<?xml version='1.0' encoding='utf-8'?>
<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd">
  <key id="d0" for="node" attr.name="label" attr.type="string" />
  <key id="d1" for="node" attr.name="type" attr.type="string" />
  <key id="d2" for="node" attr.name="community" attr.type="string" />
  <key id="d3" for="edge" attr.name="weight" attr.type="double" />
  <key id="d4" for="edge" attr.name="label" attr.type="string" />
  <key id="d5" for="node" attr.name="description" attr.type="string" />
  <key id="d6" for="edge" attr.name="full_description" attr.type="string" />
  <graph id="G" edgedefault="directed">
    <node id="0">
      <data key="d0">CELGENE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">22.0</data>
      <data key="d5">Celgene is a pharmaceutical company that specializes in the development and manufacturing of drugs for the treatment of various medical conditions, particularly multiple myeloma. The company is known for producing two key drugs: Pomalyst and Imnovid.

Pomalyst, also known as pomalidomide, is a drug used for the treatment of multiple myeloma. Celgene is the lead sponsor of a clinical trial on pomalidomide for the treatment of myeloproliferative neoplasm-associated myelofibrosis, a rare and serious condition.

Imnovid, previously known as Pomalidomide Celgene, is another drug manufactured by Celgene for the treatment of multiple myeloma. The company is the sole manufacturer of Imnovid, which is a derivative of the drug Pomalyst.

Celgene's focus on developing and producing drugs for the treatment of multiple myeloma, a type of blood cancer, has been a key part of the company's business strategy. The company's expertise in this area has allowed it to bring important new treatments to market, providing patients with additional options for managing their condition.

Overall, Celgene is a leading pharmaceutical company that has made significant contributions to the field of multiple myeloma treatment through its development and manufacturing of Pomalyst and Imnovid. The company's commitment to innovation and its focus on addressing the needs of patients with this challenging disease have been instrumental in its success.</data>
    </node>
    <node id="1">
      <data key="d0">POMALIDOMIDE</data>
      <data key="d1">DRUG</data>
      <data key="d2">1.0</data>
      <data key="d5">Pomalidomide is a drug that is currently being studied in a clinical trial for the treatment of myeloproliferative neoplasm-associated myelofibrosis. Myelofibrosis is a rare type of blood cancer that can lead to the formation of scar tissue in the bone marrow, which can impair the production of healthy blood cells.

The clinical trial is investigating the use of pomalidomide as a potential treatment for myelofibrosis. Pomalidomide is a derivative of thalidomide and is believed to have anti-inflammatory and anti-angiogenic properties, which may help to reduce the symptoms and progression of myelofibrosis.

While the clinical trial is ongoing, the available information suggests that pomalidomide may be a promising treatment option for individuals with myeloproliferative neoplasm-associated myelofibrosis. However, it is important to note that the use of pomalidomide may also be associated with potential side effects.

The text mentions that pomalidomide can cause side effects, although the specific side effects are not detailed. It is common for medications, especially those used to treat serious medical conditions like cancer, to have potential side effects. These side effects can range in severity and may include things like fatigue, nausea, or changes in blood cell counts.

It is important for individuals considering pomalidomide as a treatment option to discuss the potential risks and benefits with their healthcare provider. The healthcare provider can provide more information about the specific side effects associated with pomalidomide and help to weigh the potential benefits against the risks for each individual patient.

In summary, pomalidomide is a drug that is currently being studied as a potential treatment for myeloproliferative neoplasm-associated myelofibrosis. While the clinical trial is ongoing, the available information suggests that pomalidomide may be a promising treatment option, but it is also important to be aware of the potential side effects associated with the use of this medication.</data>
    </node>
    <node id="2">
      <data key="d0">MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS</data>
      <data key="d1">CONDITION</data>
      <data key="d2">1.0</data>
      <data key="d5">Myeloproliferative neoplasm-associated myelofibrosis is the medical condition being studied in the clinical trial</data>
    </node>
    <node id="3">
      <data key="d0">GLOBAL STUDY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">A clinical study that evaluated the use of pomalidomide 0.5 mg/day in participants with MPN-associated myelofibrosis who were RBC-transfusion dependent</data>
    </node>
    <node id="4">
      <data key="d0">CHINA EXTENSION</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">6.0</data>
      <data key="d5">An extension of the global study that evaluated the use of pomalidomide 0.5 mg/day in participants with MPN-associated myelofibrosis who had severe anemia</data>
    </node>
    <node id="5">
      <data key="d0">RBC-TRANSFUSION INDEPENDENCE</data>
      <data key="d1">EVENT</data>
      <data key="d2">25.0</data>
      <data key="d5">RBC-Transfusion Independence

RBC-transfusion independence is a secondary endpoint measuring the duration of time without requiring red blood cell transfusions. The primary endpoint of the global study is defined as the absence of RBC transfusions for any consecutive 84-day interval.

This study aims to evaluate the efficacy and safety of a treatment in achieving RBC-transfusion independence. RBC-transfusion independence is an important measure as it can indicate the ability of the treatment to reduce the need for frequent blood transfusions, which can be burdensome for patients.

The study will assess the duration of time that participants are able to go without requiring RBC transfusions, with the primary endpoint focusing on a consecutive 84-day period without transfusions. This suggests that the researchers are particularly interested in evaluating the treatment's ability to provide sustained RBC-transfusion independence, rather than just temporary or intermittent periods without the need for transfusions.

By including both the primary endpoint of 84-day RBC-transfusion independence and the secondary endpoint of overall RBC-transfusion independence duration, the study can provide a comprehensive understanding of the treatment's impact on reducing the burden of frequent blood transfusions for the participants.

The results of this study will be valuable in determining the effectiveness of the treatment in achieving RBC-transfusion independence, which is an important goal for improving the quality of life and reducing the healthcare burden for individuals requiring frequent RBC transfusions.</data>
    </node>
    <node id="6">
      <data key="d0">HEMOGLOBIN INCREASE</data>
      <data key="d1">EVENT</data>
      <data key="d2">6.0</data>
      <data key="d5">The primary endpoint of the China extension study, defined as an increase in hemoglobin ≥ 15 g/L above baseline value (in the absence of RBC transfusion) for ≥ 84 consecutive days</data>
    </node>
    <node id="7">
      <data key="d0">OVERALL SURVIVAL</data>
      <data key="d1">EVENT</data>
      <data key="d2">25.0</data>
      <data key="d5">Overall Survival

Overall Survival is a secondary endpoint in a global study, defined as the time from randomization to death or the latest date when participants are known to be alive. It measures the time from randomization to death or the latest date known alive.

This endpoint provides an important measure of the effectiveness of the treatment being studied. By tracking the time until death or the latest date known alive, researchers can assess the impact of the intervention on the longevity of participants. Overall Survival is a crucial metric in evaluating the potential benefits of a new treatment, as it directly reflects the ability of the intervention to prolong life.

The descriptions provided indicate that Overall Survival is a key secondary outcome in the global study, complementing other primary endpoints. By analyzing the time to death or latest date known alive, the study can provide valuable insights into the long-term effects of the treatment and its ability to improve patient outcomes.

Overall, the comprehensive summary of the data indicates that Overall Survival is a critical measure of the efficacy of the treatment being investigated in this global study. It will allow researchers to assess the impact of the intervention on the longevity of participants, providing important information to guide future treatment decisions and improve patient care.</data>
    </node>
    <node id="8">
      <data key="d0">MYELOPROLIFERATIVE-NEOPLASM (MPN)-ASSOCIATED MYELOFIBROSIS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">1.0</data>
      <data key="d5">The medical condition being studied, which is a type of myelofibrosis associated with myeloproliferative neoplasms</data>
    </node>
    <node id="9">
      <data key="d0">RBC-TRANSFUSION DEPENDENCE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">The requirement for participants to be red blood cell (RBC) transfusion dependent in order to be eligible for the studies</data>
    </node>
    <node id="10">
      <data key="d0">SEVERE ANEMIA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">6.0</data>
      <data key="d5">The requirement for participants in the China extension study to have severe anemia, defined as ≥ 2 hemoglobin concentrations ≤ 80 g/L for ≥ 84 days immediately before enrollment</data>
    </node>
    <node id="11">
      <data key="d0">CELGENE CORPORATION</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">21.0</data>
      <data key="d5">Celgene Corporation is a pharmaceutical company that has developed and marketed the drug Pomalyst (pomalidomide) for the treatment of multiple myeloma. The company was responsible for the development of pomalidomide, a drug used in the treatment of this type of cancer.

Celgene Corporation is the manufacturer and marketer of pomalidomide, making it a key player in the pharmaceutical industry. The company has also sponsored the OPTIMISMM clinical trial, which is evaluating the safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma.

Multiple myeloma is a type of blood cancer that affects the plasma cells in the bone marrow. Pomalyst, developed by Celgene Corporation, is a medication used to treat patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Celgene Corporation's involvement in the development, manufacturing, and marketing of Pomalyst, as well as its sponsorship of the OPTIMISMM clinical trial, demonstrates the company's commitment to advancing the treatment of multiple myeloma. The comprehensive data provided indicates that Celgene Corporation is a leading pharmaceutical company in the field of multiple myeloma research and treatment.</data>
    </node>
    <node id="12">
      <data key="d0">EUROPEAN MEDICINES AGENCY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">19.0</data>
      <data key="d5">The European Medicines Agency (EMA) is the regulatory body responsible for the authorization and oversight of medicinal products in the European Union (EU). As the central regulatory authority, the EMA plays a crucial role in ensuring the safety, efficacy, and quality of drugs and therapies available to European citizens.

The EMA was responsible for assessing and approving the use of pomalidomide, a medication marketed under the brand name Imnovid, for use in the EU. The agency conducted a thorough evaluation of the drug, examining clinical trial data and other relevant information, before granting authorization for its use in the treatment of certain types of cancer.

In addition to approving Imnovid, the EMA is the organization that published the Imnovid document, which likely contains detailed information about the drug's indications, dosage, and safety profile. As the regulatory body overseeing the authorization of medicinal products in the EU, the EMA is responsible for providing comprehensive information and guidance to healthcare professionals and the public regarding approved drugs and their appropriate use.

The EMA's role as the central regulatory authority for medicines in the EU is essential in ensuring that patients have access to safe and effective treatments. By thoroughly evaluating the available evidence and data, the EMA is able to make informed decisions about the authorization and use of medicinal products, such as Imnovid, within the European market.

Overall, the European Medicines Agency is the key regulatory body responsible for the assessment, approval, and oversight of medicinal products, including Imnovid, in the European Union. Its role in ensuring the safety and efficacy of drugs available to European citizens is crucial in maintaining public trust and confidence in the healthcare system.</data>
    </node>
    <node id="13">
      <data key="d0">MULTIPLE MYELOMA</data>
      <data key="d1">EVENT</data>
      <data key="d2">13.0</data>
      <data key="d5">Multiple Myeloma is a type of cancer that affects the plasma cells, a type of white blood cell responsible for producing antibodies. It is a serious and complex condition that requires specialized treatment.

Multiple myeloma is the disease that pomalidomide, a medication, is used to treat. Pomalidomide is specifically indicated for the treatment of patients with multiple myeloma who have relapsed or become refractory to other treatments. Relapsed disease refers to a situation where the cancer has returned after a period of remission, while refractory disease indicates that the cancer has not responded to previous treatments.

Multiple myeloma is characterized by the abnormal proliferation of plasma cells in the bone marrow. These abnormal cells can crowd out healthy blood cells, leading to a variety of symptoms, including bone pain, fractures, anemia, fatigue, and an increased risk of infections. The disease can also cause kidney damage and other complications.

The treatment of multiple myeloma often involves a combination of therapies, including chemotherapy, targeted medications like pomalidomide, stem cell transplants, and supportive care to manage the symptoms and complications of the disease. The specific treatment approach will depend on the stage and characteristics of the disease, as well as the patient's overall health and response to previous treatments.

In summary, multiple myeloma is a complex and serious form of cancer that affects the plasma cells in the bone marrow. Pomalidomide is a medication that is used to treat patients with multiple myeloma who have relapsed or become refractory to other treatments. The management of multiple myeloma often requires a multifaceted approach, with the goal of controlling the disease, managing symptoms, and improving the patient's quality of life.</data>
    </node>
    <node id="14">
      <data key="d0">DEXAMETHASONE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Dexamethasone is a corticosteroid drug that is being studied and used in combination with various medications to treat relapsed or refractory multiple myeloma, a type of blood cancer.

Multiple studies and clinical trials have investigated the use of dexamethasone in combination with other drugs for the treatment of multiple myeloma. Specifically, dexamethasone has been studied in combination with pomalidomide (also known as Pomalyst or Imnovid) and bortezomib (a proteasome inhibitor) for the treatment of relapsed or refractory multiple myeloma.

The available descriptions indicate that dexamethasone is used in combination with pomalidomide to treat multiple myeloma, including relapsed and refractory cases. Some sources also mention the use of dexamethasone in combination with bortezomib for the treatment of relapsed/refractory multiple myeloma.

While the descriptions provide consistent information about the use of dexamethasone in combination with pomalidomide and/or bortezomib for the treatment of multiple myeloma, there are no apparent contradictions in the data provided. The descriptions collectively suggest that dexamethasone is a corticosteroid drug that is used as part of combination therapy regimens to manage relapsed or refractory multiple myeloma, a serious and challenging form of blood cancer.

In summary, dexamethasone is a corticosteroid drug that is used in combination with other medications, such as pomalidomide and bortezomib, to treat relapsed or refractory multiple myeloma. This combination therapy approach aims to improve outcomes for patients with this difficult-to-treat form of blood cancer.</data>
    </node>
    <node id="15">
      <data key="d0">LENALIDOMIDE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">14.0</data>
      <data key="d5">Lenalidomide is a drug that is used in the treatment of multiple myeloma, a type of blood cancer. It is an immunomodulatory drug, which means it helps the immune system fight the cancer cells.

Patients with relapsed or refractory multiple myeloma, meaning their cancer has returned or has not responded to previous treatments, have often received lenalidomide as part of their treatment regimen. In these cases, the patients were refractory, or resistant, to lenalidomide prior to receiving other treatments.

Lenalidomide is considered a prior treatment that patients must have received before being eligible for treatment with another drug called pomalidomide. Similarly, patients must have received at least one treatment regimen that included lenalidomide in order to be eligible for treatment with Imnovid, another medication used for multiple myeloma.

The descriptions provided indicate that lenalidomide is a commonly used drug in the treatment of multiple myeloma, both as a primary treatment and as part of a prior treatment regimen. Patients with relapsed or refractory disease have often received lenalidomide, but have become resistant to it, necessitating the use of other medications like pomalidomide or Imnovid.

In summary, lenalidomide is an important immunomodulatory drug used in the treatment of multiple myeloma. Patients with relapsed or refractory disease have often received lenalidomide as part of their treatment, but have become resistant to it, leading to the use of other medications as part of their ongoing care.</data>
    </node>
    <node id="16">
      <data key="d0">BORTEZOMIB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Bortezomib is a cancer medicine that is used in the treatment of multiple myeloma, a type of blood cancer. It is a proteasome inhibitor drug that has been used in various combinations to treat patients with relapsed or refractory multiple myeloma.

Bortezomib has been used in combination with other drugs, such as Imnovid (pomalidomide) and dexamethasone, to treat multiple myeloma. It has also been studied in combination with pomalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma.

Patients with relapsed or refractory multiple myeloma have often been previously treated with bortezomib before receiving other treatments, such as pomalidomide. Bortezomib has been a prior treatment option for these patients.

In summary, bortezomib is a cancer medicine that is used in the treatment of multiple myeloma, both as a standalone treatment and in combination with other drugs, such as Imnovid and dexamethasone, or pomalidomide and dexamethasone. It is a proteasome inhibitor drug that has been used to treat patients with relapsed or refractory multiple myeloma, who have often received bortezomib as a prior treatment before being treated with other therapies.</data>
    </node>
    <node id="17">
      <data key="d0">HOFFMANN M</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Hoffmann M is a researcher who studied the absorption, metabolism, and excretion of pomalidomide in humans</data>
    </node>
    <node id="18">
      <data key="d0">KASSERRA C</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Kasserra C is a researcher who studied the drug-drug interaction potential of pomalidomide</data>
    </node>
    <node id="19">
      <data key="d0">REYES J</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Reyes J is a researcher who studied the absorption, metabolism and excretion of pomalidomide in humans</data>
    </node>
    <node id="20">
      <data key="d0">MATSUE K</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Matsue K is a researcher who studied pomalidomide alone or in combination with dexamethasone in Japanese patients with multiple myeloma</data>
    </node>
    <node id="21">
      <data key="d0">IWASAKI H</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Iwasaki H is a researcher who studied pomalidomide alone or in combination with dexamethasone in Japanese patients with multiple myeloma</data>
    </node>
    <node id="22">
      <data key="d0">CHOU T</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Chou T is a researcher who studied pomalidomide alone or in combination with dexamethasone in Japanese patients with multiple myeloma</data>
    </node>
    <node id="23">
      <data key="d0">RICHARDSON PG</data>
      <data key="d1">PERSON</data>
      <data key="d2">16.0</data>
      <data key="d5">Richardson PG is a prominent researcher who has made significant contributions to the field of multiple myeloma treatment. He has conducted extensive research on the use of pomalidomide, either alone or in combination with other therapies, for the treatment of relapsed and refractory multiple myeloma.

Richardson PG has presented his research findings at various conferences and has published his work in peer-reviewed journals. One of his notable presentations was on a phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone in relapsed/refractory multiple myeloma, which he presented as abstract MM-005.

In addition to the phase I trial, Richardson PG has also published studies on the use of pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma. His research has demonstrated the potential of pomalidomide as a new immunomodulatory agent with potent antiproliferative effects, making it a promising treatment option for patients with relapsed and refractory multiple myeloma.

Furthermore, Richardson PG has studied the use of pomalidomide alone or in combination with low-dose dexamethasone in the treatment of relapsed and refractory multiple myeloma. His research has provided valuable insights into the efficacy and safety of these treatment approaches, which can help guide clinicians in their decision-making process when managing patients with this challenging disease.

Overall, Richardson PG's extensive research on the use of pomalidomide in the treatment of relapsed and refractory multiple myeloma has made him a respected and influential figure in the field. His work has contributed to the advancement of treatment options for patients with this complex and often difficult-to-treat condition.</data>
    </node>
    <node id="24">
      <data key="d0">SIEGEL DS</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">SIEGEL DS is a researcher who has made significant contributions to the field of multiple myeloma research. Siegel DS has published studies on the use of pomalidomide, both alone and in combination with low-dose dexamethasone, in the treatment of relapsed and refractory multiple myeloma.

Siegel DS's research has focused on exploring the efficacy of pomalidomide, an immunomodulatory drug, in patients with multiple myeloma who have relapsed or become refractory to other treatments. In one study, Siegel DS and colleagues investigated the use of pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma. The results of this study demonstrated that this combination therapy was effective in improving outcomes for these patients, who often have limited treatment options.

Additionally, Siegel DS has also studied the use of pomalidomide alone or in combination with low-dose dexamethasone in the treatment of relapsed and refractory multiple myeloma. These studies have provided valuable insights into the potential benefits of this therapeutic approach, which may offer a new option for patients who have exhausted other treatment options.

Overall, Siegel DS's research has contributed to a better understanding of the role of pomalidomide, both alone and in combination with other agents, in the management of relapsed and refractory multiple myeloma. This work has the potential to improve the quality of life and clinical outcomes for patients with this challenging and often-relapsing disease.</data>
    </node>
    <node id="25">
      <data key="d0">VIJ R</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Vij R is a researcher who studied pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma</data>
    </node>
    <node id="26">
      <data key="d0">SAN MIGUEL J</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">San Miguel J is a researcher who has conducted studies on the treatment of relapsed and refractory multiple myeloma. In his research, he has compared the efficacy of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone.

Multiple myeloma is a type of blood cancer that affects the plasma cells, a type of white blood cell. Relapsed and refractory multiple myeloma refers to cases where the cancer has returned or has not responded to previous treatments. Finding effective treatment options for these patients is crucial, as they often have a poorer prognosis.

San Miguel J's research has focused on evaluating the use of pomalidomide, a newer immunomodulatory drug, in combination with low-dose dexamethasone, a corticosteroid, as a potential treatment for relapsed and refractory multiple myeloma. The studies he has conducted have compared this combination therapy to the use of high-dose dexamethasone alone.

The findings from San Miguel J's research suggest that the combination of pomalidomide and low-dose dexamethasone may be more effective in treating relapsed and refractory multiple myeloma compared to high-dose dexamethasone alone. The studies have provided valuable insights into the potential benefits of this treatment approach for patients with this challenging form of the disease.

Overall, San Miguel J's work has contributed to the ongoing efforts to improve the management and outcomes for patients with relapsed and refractory multiple myeloma. His research has helped to expand the understanding of the potential role of pomalidomide and low-dose dexamethasone in the treatment of this complex and often difficult-to-treat condition.</data>
    </node>
    <node id="27">
      <data key="d0">WEISEL K</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Weisel K is a researcher who has published studies on the use of pomalidomide in relapsed and refractory multiple myeloma. Weisel K's research has focused on investigating the efficacy of pomalidomide, a drug used to treat multiple myeloma, a type of blood cancer.

Multiple myeloma is a cancer that affects plasma cells, a type of white blood cell. Relapsed and refractory multiple myeloma refers to cases where the cancer has returned after initial treatment or has become resistant to standard therapies. Pomalidomide is a medication that has been approved for the treatment of relapsed and refractory multiple myeloma.

Weisel K's research has explored the use of pomalidomide, often in combination with low-dose dexamethasone, a corticosteroid, in patients with relapsed and refractory multiple myeloma. The studies conducted by Weisel K have provided valuable insights into the potential benefits of this treatment approach for individuals struggling with this challenging form of the disease.

Through Weisel K's research, the scientific community has gained a better understanding of the efficacy and safety of pomalidomide-based regimens in the management of relapsed and refractory multiple myeloma. The findings from Weisel K's studies have contributed to the ongoing efforts to improve the treatment options and outcomes for patients with this complex and often difficult-to-treat form of cancer.

Overall, Weisel K's research has focused on exploring the potential of pomalidomide, either alone or in combination with other therapies, as a treatment option for individuals with relapsed and refractory multiple myeloma. The insights gained from Weisel K's work have the potential to inform clinical decision-making and enhance the care and management of patients facing this challenging disease.</data>
    </node>
    <node id="28">
      <data key="d0">MOREAU P</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Moreau P is a researcher who has conducted studies on the treatment of relapsed and refractory multiple myeloma. In one of his studies, he compared the efficacy of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in patients with relapsed and refractory multiple myeloma. The study aimed to evaluate the effectiveness of this combination therapy in improving outcomes for individuals with this challenging form of the disease.

Moreau P's research has focused on exploring new treatment approaches for patients with relapsed and refractory multiple myeloma, a condition that can be particularly difficult to manage. Multiple myeloma is a type of blood cancer that affects the plasma cells, which are responsible for producing antibodies. Relapsed and refractory multiple myeloma refers to cases where the disease has returned or progressed despite previous treatments.

In his study, Moreau P investigated the use of pomalidomide, a novel immunomodulatory drug, in combination with low-dose dexamethasone, a corticosteroid medication. The study compared the outcomes of this combination therapy to the use of high-dose dexamethasone alone in patients with relapsed and refractory multiple myeloma. By conducting this comparative analysis, Moreau P aimed to provide valuable insights into the potential benefits of the pomalidomide and low-dose dexamethasone approach for this patient population.

The findings of Moreau P's research have the potential to contribute to the ongoing efforts to improve the management and treatment of relapsed and refractory multiple myeloma. By exploring innovative therapeutic strategies, such as the combination of pomalidomide and low-dose dexamethasone, Moreau P's work may help to identify more effective and well-tolerated treatment options for individuals living with this challenging form of the disease.

Overall, Moreau P's research has focused on advancing the understanding and treatment of relapsed and refractory multiple myeloma, a condition that continues to pose significant challenges for healthcare providers and patients alike. His work in comparing the efficacy of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone may help to inform future treatment decisions and improve outcomes for individuals affected by this complex and often difficult-to-treat form of multiple myeloma.</data>
    </node>
    <node id="29">
      <data key="d0">DIMOPOULOS MA</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Dimopoulos MA is a researcher who has published studies on the use of pomalidomide in relapsed and refractory multiple myeloma. He has investigated the safety and efficacy of pomalidomide, an immunomodulatory drug, in combination with low-dose dexamethasone for the treatment of refractory multiple myeloma.

Multiple myeloma is a type of blood cancer that affects plasma cells, a type of white blood cell. Relapsed and refractory multiple myeloma refers to cases where the disease has returned after initial treatment or has not responded to previous therapies. Effective treatment options for these patients are limited, making the research conducted by Dimopoulos MA particularly important.

Dimopoulos MA's studies have focused on evaluating the use of pomalidomide, a newer immunomodulatory drug, in patients with relapsed and refractory multiple myeloma. Immunomodulatory drugs work by modulating the immune system to help fight the cancer cells. Pomalidomide has shown promise as a potential treatment option for these patients, who often have limited alternatives.

In one of his studies, Dimopoulos MA and his team assessed the safety and efficacy of pomalidomide plus low-dose dexamethasone, a corticosteroid, in patients with refractory multiple myeloma. The results of this study demonstrated that this combination therapy was effective in improving outcomes for these patients, with a manageable safety profile.

Dimopoulos MA's research has contributed to a better understanding of the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma. His findings have helped to inform clinical practice and guide the development of new treatment strategies for this challenging disease.

Overall, Dimopoulos MA's work as a researcher has focused on exploring innovative approaches to the management of relapsed and refractory multiple myeloma, with the goal of improving outcomes for patients with this serious and often difficult-to-treat condition.</data>
    </node>
    <node id="30">
      <data key="d0">PALUMBO A</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Palumbo A is a researcher who studied the impact of age on outcomes in patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone</data>
    </node>
    <node id="31">
      <data key="d0">CORRADINI P</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Corradini P is a researcher who studied the safety and efficacy of pomalidomide plus low-dose dexamethasone in refractory multiple myeloma</data>
    </node>
    <node id="32">
      <data key="d0">ICHINOHE T</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Ichinohe T is a researcher who studied pomalidomide plus dexamethasone in Japanese patients with relapsed and refractory multiple myeloma</data>
    </node>
    <node id="33">
      <data key="d0">KURODA Y</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Kuroda Y is a researcher who studied pomalidomide plus dexamethasone in Japanese patients with relapsed and refractory multiple myeloma</data>
    </node>
    <node id="34">
      <data key="d0">OKAMOTO S</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Okamoto S is a researcher who studied pomalidomide plus dexamethasone in Japanese patients with relapsed and refractory multiple myeloma</data>
    </node>
    <node id="35">
      <data key="d0">CHNG WJ</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Chng WJ is a researcher who studied pomalidomide plus dexamethasone in Asian patients with relapsed/refractory myeloma</data>
    </node>
    <node id="36">
      <data key="d0">KIM K</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Kim K is a researcher who studied pomalidomide plus dexamethasone in Asian patients with relapsed/refractory myeloma</data>
    </node>
    <node id="37">
      <data key="d0">HUANG J</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Huang J is a researcher who studied pomalidomide plus dexamethasone in Asian patients with relapsed/refractory myeloma</data>
    </node>
    <node id="38">
      <data key="d0">RENAL IMPAIRMENT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">1.0</data>
      <data key="d5">Renal Impairment

Renal impairment is a condition affecting kidney function that was seen in some patients with multiple myeloma. Multiple myeloma is a type of cancer that affects plasma cells, a type of white blood cell, and can lead to various complications, including renal impairment.

Renal impairment refers to reduced kidney function in multiple myeloma patients. The kidneys play a crucial role in filtering waste and excess fluids from the body, and when their function is impaired, it can lead to a buildup of these substances, which can be harmful to the body.

The descriptions provided indicate that renal impairment is a common complication of multiple myeloma, as the cancer can directly affect the kidneys or lead to the accumulation of proteins and other substances that can damage the kidneys. This can result in a decline in the kidneys' ability to function properly, leading to a range of symptoms and potential complications.

It is important for healthcare providers to closely monitor the kidney function of patients with multiple myeloma and to take appropriate measures to manage any renal impairment that may develop. This may involve adjusting treatment plans, providing supportive care, and addressing any underlying causes of the renal impairment.

Overall, the information provided suggests that renal impairment is a significant concern for patients with multiple myeloma and that it is important for healthcare providers to be vigilant in monitoring and managing this condition to ensure the best possible outcomes for their patients.</data>
    </node>
    <node id="39">
      <data key="d0">NATIONAL COMPREHENSIVE CANCER NETWORK</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">13.0</data>
      <data key="d5">The National Comprehensive Cancer Network (NCCN) is a non-profit alliance of leading cancer centers dedicated to improving the quality, effectiveness, and efficiency of cancer care. The NCCN is responsible for developing and publishing clinical practice guidelines for the treatment of various types of cancer, including multiple myeloma.

Multiple myeloma is a type of blood cancer that affects the plasma cells in the bone marrow. The NCCN has provided comprehensive clinical practice guidelines for the treatment of multiple myeloma, which are widely recognized and used by healthcare professionals around the world.

The NCCN's guidelines for multiple myeloma cover a range of topics, including diagnosis, staging, treatment options, and supportive care. These guidelines are based on the latest scientific evidence and are regularly updated to reflect advancements in the field of oncology.

The NCCN's guidelines for multiple myeloma are designed to help healthcare providers make informed decisions about the most appropriate course of treatment for their patients. The guidelines cover a variety of treatment modalities, including chemotherapy, targeted therapies, stem cell transplantation, and supportive care measures.

The NCCN's guidelines for multiple myeloma are widely respected and are considered to be the gold standard in the field of multiple myeloma treatment. Healthcare providers around the world rely on these guidelines to ensure that their patients receive the best possible care.

In summary, the National Comprehensive Cancer Network is a leading organization in the field of cancer care, and its clinical practice guidelines for the treatment of multiple myeloma are widely recognized and used by healthcare professionals around the world.</data>
    </node>
    <node id="40">
      <data key="d0">EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">13.0</data>
      <data key="d5">The European Society for Medical Oncology (ESMO) is a leading professional organization for medical oncology, dedicated to advancing cancer care and research. The society has a significant role in providing clinical practice guidelines for the diagnosis, treatment, and follow-up of various types of cancer, including multiple myeloma.

Regarding multiple myeloma, ESMO has developed comprehensive guidelines to assist healthcare professionals in the management of this complex hematological malignancy. The guidelines cover the entire spectrum of care, from initial diagnosis to ongoing treatment and follow-up.

The ESMO guidelines for multiple myeloma provide recommendations for the appropriate diagnostic workup, including laboratory tests, imaging studies, and genetic analysis. This information helps clinicians accurately diagnose multiple myeloma and determine the stage and risk profile of the disease, which is crucial for guiding the most suitable treatment approach.

In terms of treatment, the ESMO guidelines outline the various therapeutic options available for patients with multiple myeloma. These include induction therapy, consolidation, and maintenance treatments, as well as the appropriate use of autologous stem cell transplantation. The guidelines also address the management of relapsed or refractory disease, providing guidance on the selection of salvage therapies.

The ESMO guidelines emphasize the importance of a multidisciplinary approach to the care of patients with multiple myeloma, involving hematologists, oncologists, radiologists, and other healthcare professionals. This collaborative effort ensures that patients receive comprehensive and coordinated care throughout their disease journey.

Furthermore, the ESMO guidelines provide recommendations for the follow-up and monitoring of patients with multiple myeloma, including the frequency and type of assessments required to detect disease progression or relapse. This information helps healthcare providers optimize the long-term management of their patients and improve overall outcomes.

In summary, the European Society for Medical Oncology plays a pivotal role in the field of multiple myeloma by developing and disseminating comprehensive clinical practice guidelines. These guidelines serve as a valuable resource for healthcare professionals, ensuring that patients with multiple myeloma receive evidence-based, high-quality care throughout the continuum of their disease.</data>
    </node>
    <node id="41">
      <data key="d0">ASIAN MYELOMA NETWORK</data>
      <data key="d1" />
      <data key="d2">1.0</data>
      <data key="d5" />
    </node>
    <node id="42">
      <data key="d0">DARATUMUMAB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">13.0</data>
      <data key="d5">
Daratumumab is a drug used in the treatment of multiple myeloma</data>
    </node>
    <node id="43">
      <data key="d0">IMNOVID®</data>
      <data key="d1" />
      <data key="d2">1.0</data>
      <data key="d5" />
    </node>
    <node id="44">
      <data key="d0">PREGNANCY PREVENTION PROGRAM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">1.0</data>
      <data key="d5">Patients taking pomalidomide must participate in a pregnancy prevention program due to the risk of severe abnormalities in developing babies.</data>
    </node>
    <node id="45">
      <data key="d0">CONTRACEPTION</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">1.0</data>
      <data key="d5">Patients taking pomalidomide must use effective contraception such as an implant, injection or progesterone-only pill to prevent pregnancy during and after treatment.</data>
    </node>
    <node id="46">
      <data key="d0">CANCER TEAM</data>
      <data key="d1" />
      <data key="d2">1.0</data>
      <data key="d5" />
    </node>
    <node id="47">
      <data key="d0">BLOOD TESTS</data>
      <data key="d1">EVENT</data>
      <data key="d2">1.0</data>
      <data key="d5">Patients taking pomalidomide will have regular blood tests to check that it is safe for them to continue treatment.</data>
    </node>
    <node id="48">
      <data key="d0">TREATMENT CYCLES</data>
      <data key="d1">EVENT</data>
      <data key="d2">1.0</data>
      <data key="d5">Patients typically have a course of several treatment cycles, with each cycle consisting of days of treatment and rest days.</data>
    </node>
    <node id="49">
      <data key="d0">ANTI-SICKNESS DRUGS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">1.0</data>
      <data key="d5">Patients may be given anti-sickness drugs to take home along with the pomalidomide capsules.</data>
    </node>
    <node id="50">
      <data key="d0">MOOD CHANGES</data>
      <data key="d1" />
      <data key="d2">1.0</data>
      <data key="d5" />
    </node>
    <node id="51">
      <data key="d0">BLURRY VISION</data>
      <data key="d1" />
      <data key="d2">1.0</data>
      <data key="d5" />
    </node>
    <node id="52">
      <data key="d0">CATARACTS</data>
      <data key="d1" />
      <data key="d2">1.0</data>
      <data key="d5" />
    </node>
    <node id="53">
      <data key="d0">BLOOD DONATION</data>
      <data key="d1" />
      <data key="d2">1.0</data>
      <data key="d5" />
    </node>
    <node id="54">
      <data key="d0">OTHER MEDICINES</data>
      <data key="d1" />
      <data key="d2">1.0</data>
      <data key="d5" />
    </node>
    <node id="55">
      <data key="d0">BREASTFEEDING</data>
      <data key="d1" />
      <data key="d2">20.0</data>
      <data key="d5" />
    </node>
    <node id="56">
      <data key="d0">FERTILITY</data>
      <data key="d1" />
      <data key="d2">1.0</data>
      <data key="d5" />
    </node>
    <node id="57">
      <data key="d0">MM-002</data>
      <data key="d1">EVENT</data>
      <data key="d2">1.0</data>
      <data key="d5">A pivotal phase II trial of pomalidomide plus low-dose dexamethasone</data>
    </node>
    <node id="58">
      <data key="d0">MM-003</data>
      <data key="d1">EVENT</data>
      <data key="d2">16.0</data>
      <data key="d5">A pivotal phase III trial of pomalidomide plus low-dose dexamethasone</data>
    </node>
    <node id="59">
      <data key="d0">LESLEY J. SCOTT</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Lesley J. Scott is the author of the review on pomalidomide</data>
    </node>
    <node id="60">
      <data key="d0">IMNOVID</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">17.0</data>
      <data key="d5">IMNOVID

IMNOVID is a medicinal product that has been evaluated and approved by the European Medicines Agency. It is the brand name for the drug pomalidomide, which is used to treat multiple myeloma, a type of blood cancer.

Pomalidomide, the active ingredient in IMNOVID, was previously known as Pomalidomide Celgene, as it is manufactured by the pharmaceutical company Celgene. IMNOVID is the brand name for pomalidomide in the European Union (EU).

The product information for IMNOVID is available in all official EU languages, making it accessible to patients and healthcare professionals across the region. IMNOVID is a medicine that has been thoroughly evaluated and approved for use in the treatment of multiple myeloma.

Multiple myeloma is a type of blood cancer that affects the plasma cells, a type of white blood cell. IMNOVID is used to treat patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.

IMNOVID works by modulating the immune system and inhibiting the growth and survival of myeloma cells. It has been shown to be effective in improving progression-free survival and overall survival in patients with relapsed or refractory multiple myeloma.

The safety and efficacy of IMNOVID have been established through clinical trials involving hundreds of patients. The most common side effects associated with IMNOVID include fatigue, diarrhea, constipation, peripheral neuropathy, and low blood cell counts.

Healthcare professionals are advised to closely monitor patients taking IMNOVID and manage any adverse events that may occur. Patients should follow the instructions provided by their healthcare team and report any side effects or concerns promptly.

In summary, IMNOVID is a medicinal product approved by the European Medicines Agency for the treatment of multiple myeloma. It is the brand name for the drug pomalidomide, which is manufactured by Celgene. IMNOVID has been shown to be effective in improving outcomes for patients with relapsed or refractory multiple myeloma, and its safety and efficacy have been well-established through clinical trials.</data>
    </node>
    <node id="61">
      <data key="d0">POMALYST</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">20.0</data>
      <data key="d5">Pomalyst is the brand name for the drug pomalidomide, which is an anti-angiogenic drug developed by Celgene Corporation for the treatment of multiple myeloma. Pomalyst is approved for use in the United States for the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow.

Pomalyst works by inhibiting the growth of new blood vessels (angiogenesis) that feed the tumor cells, thereby starving the cancer cells and preventing their growth and spread. It is typically used in combination with other medications, such as dexamethasone, to treat patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.

The efficacy of Pomalyst in the treatment of multiple myeloma has been demonstrated in several clinical trials. These studies have shown that Pomalyst can help improve progression-free survival and overall survival in patients with relapsed or refractory multiple myeloma, meaning the cancer has returned or has not responded to previous treatments.

Pomalyst is available in the form of oral capsules and is typically taken once daily. The dosage and duration of treatment may vary depending on the individual patient's response and tolerability to the medication.

It is important to note that, as with any medication, Pomalyst may have potential side effects, which can include fatigue, diarrhea, constipation, and low blood cell counts. Patients should discuss the potential risks and benefits of Pomalyst with their healthcare providers to determine if it is the appropriate treatment option for their specific case.

In summary, Pomalyst is an anti-angiogenic drug developed by Celgene Corporation for the treatment of multiple myeloma. It is approved for use in the United States and has been shown to be effective in improving outcomes for patients with relapsed or refractory multiple myeloma when used in combination with other therapies.</data>
    </node>
    <node id="62">
      <data key="d0">BRITISH COMMITTEE FOR STANDARDS IN HAEMATOLOGY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">13.0</data>
      <data key="d5">The British Committee for Standards in Haematology provided guidelines for the diagnosis and management of multiple myeloma</data>
    </node>
    <node id="63">
      <data key="d0">UK MYELOMA FORUM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">13.0</data>
      <data key="d5">The UK Myeloma Forum provided guidelines for the diagnosis and management of multiple myeloma</data>
    </node>
    <node id="64">
      <data key="d0">SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROGRAM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">13.0</data>
      <data key="d5">The Surveillance, Epidemiology, and End Results Program is a program of the National Cancer Institute that provides cancer statistics</data>
    </node>
    <node id="65">
      <data key="d0">ADIS DRUG EVALUATION</data>
      <data key="d1" />
      <data key="d2">1.0</data>
      <data key="d5" />
    </node>
    <node id="66">
      <data key="d0">LACY MQ</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Lacy MQ is a researcher and author who has studied and written about the use of pomalidomide in the treatment of relapsed multiple myeloma. 

Lacy MQ's research has focused on investigating pomalidomide, a new immunomodulatory agent, and its potential therapeutic effects for patients with relapsed multiple myeloma. Multiple myeloma is a type of blood cancer that affects plasma cells, and relapsed multiple myeloma refers to cases where the cancer has returned after a period of remission.

Through their research, Lacy MQ has explored the potent antiproliferative effects of pomalidomide, meaning its ability to inhibit the growth and division of cancer cells. This suggests that pomalidomide may be an effective treatment option for individuals with relapsed multiple myeloma, who often face limited treatment options and poor prognoses.

In addition to their research activities, Lacy MQ has also authored publications that discuss the use of pomalidomide in the context of multiple myeloma treatment. These publications likely serve to disseminate the findings of their research and contribute to the broader understanding of this potential therapeutic approach within the medical and scientific community.

Overall, Lacy MQ's work has focused on exploring the clinical applications of pomalidomide, a novel immunomodulatory agent, in the management of relapsed multiple myeloma. Their research and publications have the potential to inform and advance the development of new treatment strategies for this challenging and often refractory form of blood cancer.</data>
    </node>
    <node id="67">
      <data key="d0">CEREBLON</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">14.0</data>
      <data key="d5">Cereblon is a protein that is required for the antimyeloma activity of lenalidomide and pomalidomide</data>
    </node>
    <node id="68">
      <data key="d0">CC-4047</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">13.0</data>
      <data key="d5">CC-4047 is an immunomodulatory thalidomide analog that has been studied in relapsed or refractory multiple myeloma</data>
    </node>
    <node id="69">
      <data key="d0">VIJI R</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Vij R is a researcher who published a study on the use of pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma</data>
    </node>
    <node id="70">
      <data key="d0">SONG KW</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Song KW is a researcher who published studies on the use of pomalidomide in relapsed and refractory multiple myeloma</data>
    </node>
    <node id="71">
      <data key="d0">LELEU X</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Leleu X is a researcher who published studies on the use of pomalidomide in relapsed or refractory multiple myeloma</data>
    </node>
    <node id="72">
      <data key="d0">ATTAL M</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Attal M is a researcher who published a study on the use of pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma</data>
    </node>
    <node id="73">
      <data key="d0">ARNULF B</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Arnulf B is a researcher who published a study on the use of pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma</data>
    </node>
    <node id="74">
      <data key="d0">MARCO M</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Marco M is a researcher who published a study on the use of pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma with certain genetic abnormalities</data>
    </node>
    <node id="75">
      <data key="d0">KARLIN L</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Karlin L is a researcher who published a study on the use of pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma with certain genetic abnormalities</data>
    </node>
    <node id="76">
      <data key="d0">SHORT KD</data>
      <data key="d1">PERSON</data>
      <data key="d2">13.0</data>
      <data key="d5">Short KD is a researcher who has published studies on the incidence of extramedullary disease in multiple myeloma patients. Extramedullary disease refers to the presence of myeloma cells outside of the bone marrow, which can be a complication of multiple myeloma, a type of blood cancer.

In their research, Short KD has investigated the prevalence and characteristics of extramedullary disease in individuals with multiple myeloma. Multiple myeloma is a cancer that originates in the plasma cells, a type of white blood cell, and can lead to the accumulation of abnormal plasma cells in the bone marrow. Extramedullary disease occurs when these abnormal plasma cells spread to other organs or tissues outside of the bone marrow.

The studies conducted by Short KD have provided valuable insights into the incidence and clinical implications of extramedullary disease in multiple myeloma patients. By analyzing data from multiple myeloma patients, Short KD has been able to shed light on the factors that may contribute to the development of extramedullary disease, as well as the potential impact on patient outcomes.

The findings from Short KD's research may help healthcare providers better understand the progression of multiple myeloma and develop more effective treatment strategies for patients with extramedullary disease. This information can be crucial in improving the overall management and care of individuals living with multiple myeloma.

Overall, Short KD's work as a researcher has contributed to the growing body of knowledge surrounding the complexities of multiple myeloma and the challenges associated with extramedullary disease. Their research efforts have the potential to positively impact the lives of multiple myeloma patients and advance the field of hematology and oncology.</data>
    </node>
    <node id="77">
      <data key="d0">RAJKUMAR SV</data>
      <data key="d1">PERSON</data>
      <data key="d2">13.0</data>
      <data key="d5">Rajkumar SV is a researcher who has published studies on the incidence of extramedullary disease in multiple myeloma patients. Extramedullary disease refers to the presence of myeloma cells outside of the bone marrow, which can be a complication of multiple myeloma, a type of blood cancer.

Rajkumar SV's research has focused on investigating the prevalence and characteristics of extramedullary disease in individuals with multiple myeloma. Multiple myeloma is a cancer that affects plasma cells, a type of white blood cell, and can lead to the accumulation of abnormal plasma cells in the bone marrow. In some cases, these myeloma cells can spread to other parts of the body, resulting in extramedullary disease.

Through his studies, Rajkumar SV has contributed to the understanding of the incidence and clinical implications of extramedullary disease in multiple myeloma patients. His research has provided valuable insights into the factors that may contribute to the development of extramedullary disease, as well as the potential impact on patient outcomes and treatment strategies.

Rajkumar SV's work has been published in peer-reviewed scientific journals, where his findings have been shared with the broader medical and research community. By disseminating his research, Rajkumar SV has helped to advance the understanding of this important aspect of multiple myeloma and its management.

Overall, Rajkumar SV's research on the incidence of extramedullary disease in multiple myeloma patients has made significant contributions to the field of hematology and oncology. His work has the potential to inform clinical decision-making and improve the care and outcomes for individuals living with this complex and challenging form of blood cancer.</data>
    </node>
    <node id="78">
      <data key="d0">LARSON D</data>
      <data key="d1">PERSON</data>
      <data key="d2">13.0</data>
      <data key="d5">Larson D is a researcher who has conducted studies on the incidence of extramedullary disease in multiple myeloma patients. Based on the provided descriptions, Larson D has published a study on this topic, and has also more broadly studied the incidence of extramedullary disease in multiple myeloma patients.

Extramedullary disease in multiple myeloma refers to the development of tumors or lesions outside of the bone marrow, which is the primary site of the disease. This can be an important clinical consideration, as extramedullary involvement can impact disease progression and treatment response.

Larson D's research has likely focused on understanding the prevalence of extramedullary disease in multiple myeloma patients, as well as any associated risk factors or prognostic implications. The published study may have provided data on the incidence rates of extramedullary disease, and potentially explored factors that contribute to its development in some patients.

By studying this aspect of multiple myeloma, Larson D's work has likely contributed to the broader understanding of the disease and its clinical manifestations. This information can be valuable for healthcare providers in terms of monitoring patients, making treatment decisions, and developing more targeted therapeutic approaches.

Overall, Larson D appears to be a researcher who has made contributions to the field of multiple myeloma, with a specific focus on the incidence and implications of extramedullary disease in these patients. Their research findings may have important clinical relevance and could help inform the management of this complex hematological malignancy.</data>
    </node>
    <node id="79">
      <data key="d0">CELEGENE CORPORATION</data>
      <data key="d1" />
      <data key="d2">16.0</data>
      <data key="d5" />
    </node>
    <node id="80">
      <data key="d0">EUDRA CT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">1.0</data>
      <data key="d5">The EU Clinical Trials Register where a clinical trial on pomalidomide was registered</data>
    </node>
    <node id="81">
      <data key="d0">CLINICALTRIALSREGISTER.EU</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">1.0</data>
      <data key="d5">The EU Clinical Trials Register website</data>
    </node>
    <node id="82">
      <data key="d0">BLOOD</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">1.0</data>
      <data key="d5">The medical journal where studies on pomalidomide were published</data>
    </node>
    <node id="83">
      <data key="d0">LANCET ONCOL</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">1.0</data>
      <data key="d5">The medical journal where a study on pomalidomide was published</data>
    </node>
    <node id="84">
      <data key="d0">AMERICAN SOCIETY OF HEMATOLOGY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">26.0</data>
      <data key="d5">The American Society of Hematology (ASH) is a professional organization for hematologists, which is a medical specialty focused on the study and treatment of blood disorders. The organization hosts an annual meeting where the latest research and advancements in hematology are presented.

At the ASH annual meeting, multiple studies on the drug pomalidomide were presented. Pomalidomide is a medication used in the treatment of certain blood cancers, such as multiple myeloma. The studies showcased at the ASH meeting likely provided new insights and data on the efficacy and safety of pomalidomide in treating these hematological conditions.

The American Society of Hematology serves as a hub for hematology professionals to share their research, collaborate, and stay up-to-date on the latest developments in the field. The organization's annual meeting is a significant event in the hematology community, attracting researchers, clinicians, and industry representatives from around the world to discuss the most pressing issues and innovations in blood-related diseases and their treatments.

Through its various initiatives, publications, and educational programs, the American Society of Hematology aims to advance the understanding and management of hematological disorders, ultimately improving patient outcomes and the overall quality of care in this medical specialty.</data>
    </node>
    <node id="85">
      <data key="d0">DELETION 17P</data>
      <data key="d1">GEO</data>
      <data key="d2">13.0</data>
      <data key="d5">Deletion 17p is a genetic abnormality associated with multiple myeloma</data>
    </node>
    <node id="86">
      <data key="d0">TRANSLOCATION T(4;14)</data>
      <data key="d1">GEO</data>
      <data key="d2">13.0</data>
      <data key="d5">Translocation t(4;14) is a genetic abnormality associated with multiple myeloma</data>
    </node>
    <node id="87">
      <data key="d0">EXAMETHASONE</data>
      <data key="d1" />
      <data key="d2">13.0</data>
      <data key="d5" />
    </node>
    <node id="88">
      <data key="d0">KUMAR SK</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Kumar SK is a researcher who studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </node>
    <node id="89">
      <data key="d0">LAPLANT BR</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">LaPlant BR is a researcher who studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </node>
    <node id="90">
      <data key="d0">MIKHAEL JR</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Mikhael JR is a researcher who studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </node>
    <node id="91">
      <data key="d0">HAYMAN SR</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Hayman SR is a researcher who studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </node>
    <node id="92">
      <data key="d0">LAUMANN K</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Laumann K is a researcher who studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </node>
    <node id="93">
      <data key="d0">COONEY MM</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Cooney MM is a researcher who studied pomalidomide in the treatment of solid tumors</data>
    </node>
    <node id="94">
      <data key="d0">NOCK C</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Nock C is a researcher who studied pomalidomide in the treatment of solid tumors</data>
    </node>
    <node id="95">
      <data key="d0">BOKAR J</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Bokar J is a researcher who studied pomalidomide in the treatment of solid tumors</data>
    </node>
    <node id="96">
      <data key="d0">SIEGEL D</data>
      <data key="d1">PERSON</data>
      <data key="d2">26.0</data>
      <data key="d5">Siegel D is a researcher who has conducted studies on the treatment of relapsed and refractory multiple myeloma. He presented abstract MM-005 on a phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma. This study aimed to evaluate the safety and efficacy of this combination therapy in this patient population.

Pomalidomide is an immunomodulatory drug that has shown promise in the treatment of relapsed multiple myeloma. Siegel D's research has focused on investigating the use of pomalidomide, either alone or in combination with other therapies, for the management of relapsed and refractory multiple myeloma. The phase I trial he presented evaluated the safety and tolerability of the combination of pomalidomide, bortezomib, and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.

The results of Siegel D's research suggest that this combination therapy may be a viable option for the treatment of relapsed and refractory multiple myeloma. The study provided valuable insights into the potential benefits and risks associated with this treatment approach, which could inform future clinical trials and guide the development of more effective therapies for this challenging disease.

Overall, Siegel D's work has contributed to the ongoing efforts to improve the management of relapsed and refractory multiple myeloma. His research has focused on exploring the use of novel drug combinations, such as pomalidomide, bortezomib, and dexamethasone, to enhance treatment outcomes for patients with this complex and often difficult-to-treat condition.</data>
    </node>
    <node id="97">
      <data key="d0">ALLRED JB</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Allred JB is a researcher who studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </node>
    <node id="98">
      <data key="d0">GERTZ MA</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Gertz MA is a researcher who studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </node>
    <node id="99">
      <data key="d0">JAGANNATH S</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Jagannath S is a researcher who studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </node>
    <node id="100">
      <data key="d0">HOFMEISTER CC</data>
      <data key="d1">PERSON</data>
      <data key="d2">26.0</data>
      <data key="d5">Hofmeister CC is a researcher who has made significant contributions to the field of multiple myeloma treatment. According to the provided information, Hofmeister CC presented abstract MM-005 on a phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone in relapsed/refractory multiple myeloma. This study aimed to evaluate the safety and efficacy of this combination therapy in patients with multiple myeloma who had previously relapsed or were refractory to treatment.

In addition to the phase I trial, Hofmeister CC has also studied the use of pomalidomide in the treatment of relapsed multiple myeloma. Pomalidomide is a novel immunomodulatory drug that has shown promise in the management of this challenging disease.

The descriptions provided do not appear to be contradictory, but rather complementary, highlighting Hofmeister CC's research interests and contributions in the field of multiple myeloma. The phase I trial of the combination therapy and the study on pomalidomide both focus on improving treatment options for patients with relapsed or refractory multiple myeloma, a population with significant unmet medical needs.

Hofmeister CC's research efforts are crucial in advancing our understanding of multiple myeloma and developing more effective treatment strategies. By exploring novel drug combinations and investigating the potential of emerging therapies like pomalidomide, Hofmeister CC is contributing to the ongoing efforts to improve outcomes for patients with this complex and often difficult-to-treat disease.

In summary, Hofmeister CC is a researcher who has made valuable contributions to the field of multiple myeloma treatment. Through their work on a phase I trial of a combination therapy and their study of pomalidomide, Hofmeister CC is helping to expand the treatment options and improve the prognosis for patients with relapsed or refractory multiple myeloma.</data>
    </node>
    <node id="101">
      <data key="d0">BAZ RC</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Baz RC is a researcher who studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </node>
    <node id="102">
      <data key="d0">BLADÉ J</data>
      <data key="d1">PERSON</data>
      <data key="d2">13.0</data>
      <data key="d5">Bladé J is a researcher who studied prognostic factors for multiple myeloma</data>
    </node>
    <node id="103">
      <data key="d0">ROSIÑOL L</data>
      <data key="d1">PERSON</data>
      <data key="d2">13.0</data>
      <data key="d5">Rosiñol L is a researcher who studied prognostic factors for multiple myeloma</data>
    </node>
    <node id="104">
      <data key="d0">CIBEIRA MT</data>
      <data key="d1">PERSON</data>
      <data key="d2">13.0</data>
      <data key="d5">Cibeira MT is a researcher who studied prognostic factors for multiple myeloma</data>
    </node>
    <node id="105">
      <data key="d0">ROY V</data>
      <data key="d1">PERSON</data>
      <data key="d2">1.0</data>
      <data key="d5">Roy V is a researcher who studied pomalidomide in combination with bortezomib and dexamethasone for relapsed multiple myeloma</data>
    </node>
    <node id="106">
      <data key="d0">STADTMAUER EA</data>
      <data key="d1">PERSON</data>
      <data key="d2">26.0</data>
      <data key="d5">Stadtmauer EA is a researcher who presented a phase I/II dose expansion trial of carfilzomib and pomalidomide with dexamethasone in patients with relapsed/refractory multiple myeloma</data>
    </node>
    <node id="107">
      <data key="d0">ABONOUR R</data>
      <data key="d1">PERSON</data>
      <data key="d2">26.0</data>
      <data key="d5">Abonour R is a researcher who presented a phase I/II dose expansion trial of carfilzomib and pomalidomide with dexamethasone in patients with relapsed/refractory multiple myeloma</data>
    </node>
    <node id="108">
      <data key="d0">MARTIN TG</data>
      <data key="d1">PERSON</data>
      <data key="d2">26.0</data>
      <data key="d5">Martin TG is a researcher who presented a multicenter randomized phase II trial of pomalidomide, dexamethasone with or without oral weekly cyclophosphamide for lenalidomide refractory multiple myeloma</data>
    </node>
    <node id="109">
      <data key="d0">ALSINA M</data>
      <data key="d1">PERSON</data>
      <data key="d2">26.0</data>
      <data key="d5">Alsina M is a researcher who presented a multicenter randomized phase II trial of pomalidomide, dexamethasone with or without oral weekly cyclophosphamide for lenalidomide refractory multiple myeloma</data>
    </node>
    <node id="110">
      <data key="d0">HILGER JD</data>
      <data key="d1">PERSON</data>
      <data key="d2">26.0</data>
      <data key="d5">Hilger JD is a researcher who presented results from a phase 1/2 trial of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma</data>
    </node>
    <node id="111">
      <data key="d0">KLEIN L</data>
      <data key="d1">PERSON</data>
      <data key="d2">26.0</data>
      <data key="d5">Klein L is a researcher who presented results from a phase 1/2 trial of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma</data>
    </node>
    <node id="112">
      <data key="d0">OPTIMISMM TRIAL</data>
      <data key="d1" />
      <data key="d2">21.0</data>
      <data key="d5" />
    </node>
    <node id="113">
      <data key="d0">POMALYST/IMNOVID</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">21.0</data>
      <data key="d5">POMALYST/IMNOVID is a drug developed by Celgene Corporation for the treatment of relapsed or refractory multiple myeloma</data>
    </node>
    <node id="114">
      <data key="d0">OPTIMISMM</data>
      <data key="d1">EVENT</data>
      <data key="d2">21.0</data>
      <data key="d5">OPTIMISMM is a pivotal Phase III clinical study conducted by Celgene Corporation to evaluate the efficacy and safety of POMALYST/IMNOVID plus bortezomib and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma</data>
    </node>
    <node id="115">
      <data key="d0">REVLIMID</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">13.0</data>
      <data key="d5">REVLIMID is a drug used to treat multiple myeloma, a type of blood cancer. It is manufactured by the pharmaceutical company Celgene.

REVLIMID is a medication that has been approved for the treatment of multiple myeloma, a cancer that affects the plasma cells in the bone marrow. It is considered an effective treatment option for this condition, as it helps to slow the growth and spread of the cancerous cells.

The active ingredient in REVLIMID is lenalidomide, which is a derivative of thalidomide. Lenalidomide works by modulating the immune system, inhibiting the growth of blood vessels that feed the tumor, and directly inducing the death of myeloma cells.

REVLIMID is typically prescribed in combination with other medications, such as dexamethasone, to enhance its effectiveness in treating multiple myeloma. The drug is available in the form of oral capsules and is taken on a regular schedule, as determined by the patient's healthcare provider.

Patients who are prescribed REVLIMID may experience a range of side effects, including fatigue, diarrhea, constipation, and an increased risk of blood clots. Regular monitoring and close communication with the healthcare team are important to manage these potential side effects and ensure the safe and effective use of the medication.

Overall, REVLIMID is an important treatment option for individuals diagnosed with multiple myeloma, as it has been shown to improve outcomes and quality of life for many patients. The comprehensive summary provided here aims to give a clear and concise overview of this medication, its uses, and its potential benefits and risks.</data>
    </node>
    <node id="116">
      <data key="d0">AMERICAN CANCER SOCIETY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">13.0</data>
      <data key="d5">The American Cancer Society is an organization that provides estimates on the number of new cases and deaths from multiple myeloma in the US</data>
    </node>
    <node id="117">
      <data key="d0">FOOD AND DRUG ADMINISTRATION (FDA)</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">20.0</data>
      <data key="d5">The FDA is the US regulatory agency that approved Pomalyst for the treatment of multiple myeloma in February 2013</data>
    </node>
    <node id="118">
      <data key="d0">EUROPEAN MEDICINES AGENCY (EMA)</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">17.0</data>
      <data key="d5">The European Medicines Agency (EMA) is the regulatory body responsible for authorizing the use of pharmaceutical products in the European Union. As the European regulatory agency, the EMA plays a crucial role in the approval and oversight of new medicines.

In June 2012, the pharmaceutical company Celgene submitted a marketing authorization application (MAA) to the EMA for their drug Pomalyst. This application was part of the process of seeking approval from the EMA to allow the use of Pomalyst within the European Union.

Additionally, the EMA has authorized the use of the drug Imnovid (also known as Pomalyst) in the European Union. This decision by the EMA allows for the legal distribution and prescription of Imnovid/Pomalyst to patients within the EU member states.

The EMA is responsible for evaluating the safety, efficacy, and quality of new pharmaceutical products before granting marketing authorization. This process involves a thorough review of clinical trial data and other supporting evidence provided by the drug manufacturer. Once a product is approved, the EMA continues to monitor its use and can take regulatory actions if any safety concerns arise.

As the central European regulatory body for medicines, the EMA plays a vital role in ensuring that patients across the EU have access to safe and effective pharmaceutical treatments. The agency's decisions regarding the authorization of products like Pomalyst and Imnovid are crucial in determining the availability of these medicines to healthcare providers and patients throughout Europe.</data>
    </node>
    <node id="119">
      <data key="d0">EUROPEAN COMMISSION (EC)</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">20.0</data>
      <data key="d5">The EC is the European regulatory body that approved Pomalyst (under the brand name IMNOVID) for the treatment of relapsed and refractory multiple myeloma in August 2013</data>
    </node>
    <node id="120">
      <data key="d0">PHASE I CLINICAL TRIAL</data>
      <data key="d1">EVENT</data>
      <data key="d2">20.0</data>
      <data key="d5">Celgene conducted a Phase I clinical trial on Pomalyst between August 2011 and October 2011 to evaluate the safety, efficacy, tolerability and pharmacokinetics of the drug</data>
    </node>
    <node id="121">
      <data key="d0">PHASE I/II CLINICAL TRIAL</data>
      <data key="d1">EVENT</data>
      <data key="d2">20.0</data>
      <data key="d5">Celgene initiated a Phase I/II clinical trial on Pomalyst in November 2011 to evaluate the drug in combination with high dose Dexamethasone and oral cyclophosphamide</data>
    </node>
    <node id="122">
      <data key="d0">PHASE II CLINICAL TRIAL</data>
      <data key="d1">EVENT</data>
      <data key="d2">20.0</data>
      <data key="d5">Celgene conducted a Phase II clinical trial known as CC-4047-MM-002 study to evaluate Pomalyst alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma</data>
    </node>
    <node id="123">
      <data key="d0">PHASE III CLINICAL TRIAL</data>
      <data key="d1">EVENT</data>
      <data key="d2">20.0</data>
      <data key="d5">Celgene initiated a Phase III clinical trial (MM-003) on Pomalyst in March 2011 to evaluate time to disease progression or death</data>
    </node>
    <node id="124">
      <data key="d0">FDA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">20.0</data>
      <data key="d5">The FDA approved Pomalyst based on the results from the Phase II CC-4047-MM-002 study</data>
    </node>
    <node id="125">
      <data key="d0">EC</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">20.0</data>
      <data key="d5">The EC approved Pomalyst based on the results from the Phase III MM-003 study</data>
    </node>
    <node id="126">
      <data key="d0">IRELAND</data>
      <data key="d1">GEO</data>
      <data key="d2">18.0</data>
      <data key="d5">Ireland is a country located in Western Europe. It is an island nation that is part of the United Kingdom, sharing a land border with Northern Ireland. Ireland is known for its rich cultural heritage, including its literature, music, and traditional Irish dance.

The country is home to Bristol-Myers Squibb Pharma EEIG, a pharmaceutical company that is based in Ireland. Bristol-Myers Squibb Pharma EEIG is a subsidiary of the larger Bristol-Myers Squibb company, which is a global biopharmaceutical company that develops and manufactures a wide range of medications and healthcare products.

Ireland is a developed country with a strong economy, primarily driven by the technology, pharmaceutical, and financial services sectors. The country has a population of approximately 4.9 million people and is known for its scenic landscapes, including the rugged coastlines, rolling green hills, and picturesque countryside.

Overall, Ireland is a diverse and vibrant country that offers a unique blend of cultural, historical, and economic opportunities. The presence of Bristol-Myers Squibb Pharma EEIG in the country further highlights Ireland's importance as a hub for the pharmaceutical industry.</data>
    </node>
    <node id="127">
      <data key="d0">BRISTOL MYERS SQUIBB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">1.0</data>
      <data key="d5">Bristol Myers Squibb is the pharmaceutical company that developed pomalidomide.</data>
    </node>
    <node id="128">
      <data key="d0">UNITED STATES</data>
      <data key="d1">GEO</data>
      <data key="d2">1.0</data>
      <data key="d5">Pomalidomide was approved for medical use in the United States in February 2013.</data>
    </node>
    <node id="129">
      <data key="d0">EUROPEAN UNION</data>
      <data key="d1">GEO</data>
      <data key="d2">19.0</data>
      <data key="d5">The European Union (EU) is a political and economic union of 27 member states located primarily in Europe. It is a supranational organization that has been granted certain decision-making powers by its member states.

One of the key responsibilities of the European Union is the regulation and approval of medical products for use within its member states. In this capacity, the EU has approved the use of certain pharmaceutical drugs for medical purposes.

Specifically, the drug Pomalidomide was approved for medical use in the European Union in August 2013. This approval allows for the marketing and distribution of Pomalidomide within the EU member states, making it available to patients in need of this medication.

Additionally, the drug Imnovid has also been authorized for marketing within the geographical region of the European Union. This means that Imnovid, another pharmaceutical product, has been granted approval by the relevant EU regulatory bodies for sale and use across the member states that make up the European Union.

The approval and authorization of these two drugs, Pomalidomide and Imnovid, by the European Union demonstrates the Union's role in ensuring the availability of safe and effective medical treatments for the citizens of its member states. By centralizing the regulatory process, the EU is able to provide a consistent and streamlined approach to the evaluation and approval of new drugs, ultimately benefiting the health and well-being of the European population.

In summary, the European Union, as a political and economic union, plays a significant role in the regulation and approval of medical products, including the drugs Pomalidomide and Imnovid, which have both been authorized for use within the geographical region of the EU. This highlights the EU's commitment to providing its citizens with access to necessary and approved medical treatments.</data>
    </node>
    <node id="130">
      <data key="d0">KAPOSI SARCOMA</data>
      <data key="d1">DISEASE</data>
      <data key="d2">1.0</data>
      <data key="d5">Pomalidomide is used to treat AIDS-related Kaposi sarcoma.</data>
    </node>
    <node id="131">
      <data key="d0">BRISTOL-MYERS SQUIBB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">1.0</data>
      <data key="d5">Bristol-Myers Squibb is a pharmaceutical company that is developing pomalidomide (Pomalyst/Imnovid) for the treatment of acute myelocytic leukemia.</data>
    </node>
    <node id="132">
      <data key="d0">ACUTE MYELOCYTIC LEUKEMIA</data>
      <data key="d1" />
      <data key="d2">1.0</data>
      <data key="d5" />
    </node>
    <node id="133">
      <data key="d0">ACUTE MYELOCYTIC LEUKEMIA (AML)</data>
      <data key="d1">GEO</data>
      <data key="d2">1.0</data>
      <data key="d5">Acute myelocytic leukemia (AML) is the disease indication that pomalidomide is being developed to treat</data>
    </node>
    <node id="134">
      <data key="d0">PEDIATRIC USE</data>
      <data key="d1" />
      <data key="d2">20.0</data>
      <data key="d5" />
    </node>
    <node id="135">
      <data key="d0">GERIATRIC USE</data>
      <data key="d1" />
      <data key="d2">20.0</data>
      <data key="d5" />
    </node>
    <node id="136">
      <data key="d0">HEPATIC IMPAIRMENT</data>
      <data key="d1" />
      <data key="d2">20.0</data>
      <data key="d5" />
    </node>
    <node id="137">
      <data key="d0">SMOKING</data>
      <data key="d1" />
      <data key="d2">20.0</data>
      <data key="d5" />
    </node>
    <node id="138">
      <data key="d0">BREASTFED INFANTS</data>
      <data key="d1">PERSON</data>
      <data key="d2">20.0</data>
      <data key="d5">Breastfed infants may experience adverse reactions from POMALYST excreted in breast milk</data>
    </node>
    <node id="139">
      <data key="d0">PEDIATRIC PATIENTS</data>
      <data key="d1">PERSON</data>
      <data key="d2">20.0</data>
      <data key="d5">Safety and effectiveness of POMALYST have not been established in pediatric patients</data>
    </node>
    <node id="140">
      <data key="d0">GERIATRIC PATIENTS</data>
      <data key="d1">PERSON</data>
      <data key="d2">20.0</data>
      <data key="d5">Patients over 65 years old were more likely to experience pneumonia when taking POMALYST</data>
    </node>
    <node id="141">
      <data key="d0">PATIENTS WITH RENAL IMPAIRMENT</data>
      <data key="d1">PERSON</data>
      <data key="d2">20.0</data>
      <data key="d5">Dose of POMALYST should be reduced by 25% in patients with severe renal impairment requiring dialysis</data>
    </node>
    <node id="142">
      <data key="d0">PATIENTS WITH HEPATIC IMPAIRMENT</data>
      <data key="d1">PERSON</data>
      <data key="d2">20.0</data>
      <data key="d5">Dose of POMALYST should be reduced by 25% in patients with mild to moderate hepatic impairment and 50% in patients with severe hepatic impairment</data>
    </node>
    <node id="143">
      <data key="d0">SMOKERS</data>
      <data key="d1">PERSON</data>
      <data key="d2">20.0</data>
      <data key="d5">Smoking may reduce the efficacy of POMALYST as it reduces the AUC of pomalidomide by 32% through CYP1A2 induction</data>
    </node>
    <node id="144">
      <data key="d0">RATS</data>
      <data key="d1" />
      <data key="d2">20.0</data>
      <data key="d5" />
    </node>
    <node id="145">
      <data key="d0">PREGNANCY-PREVENTION PROGRAM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">22.0</data>
      <data key="d5">The company that makes Imnovid will set up a pregnancy-prevention program in each EU member state to ensure the safe use of the medicine</data>
    </node>
    <node id="146">
      <data key="d0">MEMBER STATES</data>
      <data key="d1">GEO</data>
      <data key="d2">22.0</data>
      <data key="d5">The EU member states will ensure that educational materials and patient cards are provided to prescribers and patients for the safe use of Imnovid</data>
    </node>
    <node id="147">
      <data key="d0">RISK MANAGEMENT PLAN</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">19.0</data>
      <data key="d5">The Risk Management Plan is a document that describes the risk management system for the medicinal product Imnovid</data>
    </node>
    <node id="148">
      <data key="d0">PRODUCT INFORMATION</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">19.0</data>
      <data key="d5">The Product Information document provides details about the medicinal product Imnovid, including its composition, indications, dosage, and other relevant information</data>
    </node>
    <node id="149">
      <data key="d0">ENGLISH</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">English is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="150">
      <data key="d0">BULGARIAN</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Bulgarian is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="151">
      <data key="d0">SPANISH</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Spanish is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="152">
      <data key="d0">CZECH</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Czech is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="153">
      <data key="d0">DANISH</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Danish is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="154">
      <data key="d0">GERMAN</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">German is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="155">
      <data key="d0">ESTONIAN</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Estonian is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="156">
      <data key="d0">GREEK</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Greek is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="157">
      <data key="d0">FRENCH</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">French is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="158">
      <data key="d0">CROATIAN</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Croatian is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="159">
      <data key="d0">ICELANDIC</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Icelandic is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="160">
      <data key="d0">ITALIAN</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Italian is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="161">
      <data key="d0">LATVIAN</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Latvian is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="162">
      <data key="d0">LITHUANIAN</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Lithuanian is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="163">
      <data key="d0">HUNGARIAN</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Hungarian is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="164">
      <data key="d0">MALTESE</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Maltese is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="165">
      <data key="d0">DUTCH</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Dutch is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="166">
      <data key="d0">NORWEGIAN</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Norwegian is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="167">
      <data key="d0">POLISH</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Polish is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="168">
      <data key="d0">PORTUGUESE</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Portuguese is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="169">
      <data key="d0">ROMANIAN</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Romanian is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="170">
      <data key="d0">SLOVAK</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Slovak is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="171">
      <data key="d0">SLOVENIAN</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Slovenian is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="172">
      <data key="d0">FINNISH</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Finnish is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="173">
      <data key="d0">SWEDISH</data>
      <data key="d1">GEO</data>
      <data key="d2">17.0</data>
      <data key="d5">Swedish is one of the languages in which the product information and risk management plan for Imnovid is published</data>
    </node>
    <node id="174">
      <data key="d0">PASS</data>
      <data key="d1" />
      <data key="d2">17.0</data>
      <data key="d5" />
    </node>
    <node id="175">
      <data key="d0">ANNEX I</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">17.0</data>
      <data key="d5">Annex I contains the summary of product characteristics</data>
    </node>
    <node id="176">
      <data key="d0">ANNEX IIA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">17.0</data>
      <data key="d5">Annex IIA contains the manufacturing authorisation holder responsible for batch release</data>
    </node>
    <node id="177">
      <data key="d0">ANNEX IIB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">17.0</data>
      <data key="d5">Annex IIB contains the conditions of the marketing authorisation</data>
    </node>
    <node id="178">
      <data key="d0">ANNEX IIIA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">17.0</data>
      <data key="d5">Annex IIIA contains the labelling</data>
    </node>
    <node id="179">
      <data key="d0">ANNEX IIIB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">17.0</data>
      <data key="d5">Annex IIIB contains the package leaflet</data>
    </node>
    <node id="180">
      <data key="d0">BRISTOL-MYERS SQUIBB PHARMA EEIG</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">18.0</data>
      <data key="d5">Bristol-Myers Squibb Pharma EEIG is the marketing authorization holder for Imnovid</data>
    </node>
    <node id="181">
      <data key="d0">PLAZA 254</data>
      <data key="d1">GEO</data>
      <data key="d2">18.0</data>
      <data key="d5">The address of Bristol-Myers Squibb Pharma EEIG</data>
    </node>
    <node id="182">
      <data key="d0">BLANCHARDSTOWN CORPORATE PARK 2</data>
      <data key="d1">GEO</data>
      <data key="d2">18.0</data>
      <data key="d5">The address of Bristol-Myers Squibb Pharma EEIG</data>
    </node>
    <node id="183">
      <data key="d0">DUBLIN 15 D15 T867</data>
      <data key="d1">GEO</data>
      <data key="d2">18.0</data>
      <data key="d5">The address of Bristol-Myers Squibb Pharma EEIG</data>
    </node>
    <node id="184">
      <data key="d0">COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">17.0</data>
      <data key="d5">The CHMP is the committee within the European Medicines Agency that reviews and provides opinions on marketing authorization applications for medicinal products</data>
    </node>
    <node id="185">
      <data key="d0">COMMUNITY REGISTER OF ORPHAN MEDICINAL PRODUCTS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">17.0</data>
      <data key="d5">The Community register of orphan medicinal products is maintained by the European Medicines Agency and tracks medicines that have been granted orphan status</data>
    </node>
    <edge id="e0" source="0" target="1">
      <data key="d3">10.0</data>
      <data key="d4">lead sponsor clinical...</data>
      <data key="d6">Celgene is the lead sponsor of the clinical trial studying pomalidomide</data>
    </edge>
    <edge id="e1" source="1" target="2">
      <data key="d3">1.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Pomalidomide is being studied as a treatment for myeloproliferative neoplasm-associated myelofibrosis</data>
    </edge>
    <edge id="e2" source="3" target="1">
      <data key="d3">18.0</data>
      <data key="d4">global study...</data>
      <data key="d6">Pomalidomide was evaluated in the global study in participants with MPN-associated myelofibrosis who were RBC-transfusion dependent</data>
    </edge>
    <edge id="e3" source="3" target="5">
      <data key="d3">18.0</data>
      <data key="d4">primary endpoint...</data>
      <data key="d6">RBC-transfusion independence was the primary endpoint of the global study</data>
    </edge>
    <edge id="e4" source="3" target="7">
      <data key="d3">10.0</data>
      <data key="d4">secondary endpoint...</data>
      <data key="d6">Overall survival was a secondary endpoint of the global study</data>
    </edge>
    <edge id="e5" source="3" target="9">
      <data key="d3">9.0</data>
      <data key="d4">global study were...</data>
      <data key="d6">Participants in the global study were required to be RBC-transfusion dependent</data>
    </edge>
    <edge id="e6" source="4" target="1">
      <data key="d3">18.0</data>
      <data key="d4">China extension study...</data>
      <data key="d6">Pomalidomide was evaluated in the China extension study in participants with MPN-associated myelofibrosis who had severe anemia</data>
    </edge>
    <edge id="e7" source="4" target="6">
      <data key="d3">18.0</data>
      <data key="d4">primary endpoint...</data>
      <data key="d6">Hemoglobin increase was the primary endpoint of the China extension study</data>
    </edge>
    <edge id="e8" source="4" target="10">
      <data key="d3">1.0</data>
      <data key="d4">China extension study...</data>
      <data key="d6">Participants in the China extension study were required to have severe anemia</data>
    </edge>
    <edge id="e9" source="1" target="8">
      <data key="d3">9.0</data>
      <data key="d4">treat MPN-associated myelofibrosis...</data>
      <data key="d6">Pomalidomide was used to treat MPN-associated myelofibrosis</data>
    </edge>
    <edge id="e10" source="11" target="1">
      <data key="d3">18.0</data>
      <data key="d4">markets pomalidomide...</data>
      <data key="d6">Celgene Corporation manufactures and markets pomalidomide</data>
    </edge>
    <edge id="e11" source="12" target="1">
      <data key="d3">16.0</data>
      <data key="d4">Agency assessed approved...</data>
      <data key="d6">The European Medicines Agency assessed and approved pomalidomide for use in the European Union</data>
    </edge>
    <edge id="e12" source="13" target="1">
      <data key="d3">48.0</data>
      <data key="d4">Pomalidomide Multiple myeloma...</data>
      <data key="d6">Multiple Myeloma and Pomalidomide

Multiple myeloma is a type of blood cancer that affects plasma cells, a type of white blood cell. Pomalidomide is a drug that is used to treat relapsed and refractory multiple myeloma.

Pomalidomide is approved for the treatment of relapsed and refractory multiple myeloma. This means that it is used to treat patients whose multiple myeloma has returned or has not responded to other treatments. Pomalidomide is used in combination with other medications to help manage the symptoms of multiple myeloma and improve patient outcomes.

The descriptions provided indicate that pomalidomide is a drug that is specifically used to treat multiple myeloma, a type of blood cancer. Multiple myeloma is a condition in which abnormal plasma cells accumulate in the bone marrow, leading to the production of abnormal proteins and the displacement of healthy blood cells. This can result in a variety of symptoms, including bone pain, fatigue, and an increased risk of infections.

Pomalidomide is used to treat relapsed and refractory multiple myeloma, which means that it is used to treat patients whose multiple myeloma has returned after previous treatment or has not responded to other treatments. Pomalidomide is typically used in combination with other medications, such as dexamethasone, to help manage the symptoms of multiple myeloma and improve patient outcomes.

Overall, the data provided indicates that pomalidomide is an important treatment option for patients with relapsed and refractory multiple myeloma. By using this drug in combination with other medications, healthcare providers can help to improve the quality of life and outcomes for patients with this serious and complex condition.</data>
    </edge>
    <edge id="e13" source="1" target="14">
      <data key="d3">53.0</data>
      <data key="d4">used combination...</data>
      <data key="d6">POMALIDOMIDE and DEXAMETHASONE are used in combination to treat multiple myeloma, a type of blood cancer.

Pomalidomide is a medication that is used in combination with dexamethasone to treat relapsed and refractory multiple myeloma. Relapsed myeloma refers to cancer that has returned after a period of improvement, while refractory myeloma is cancer that does not respond to treatment. The combination of pomalidomide and dexamethasone has been studied and found to be effective in treating this type of multiple myeloma.

Dexamethasone is a corticosteroid medication that is also used in combination with pomalidomide to treat multiple myeloma. Corticosteroids like dexamethasone can help to reduce inflammation and support the immune system, which can be beneficial in the treatment of cancer.

The available data indicates that the combination of pomalidomide and dexamethasone is an effective treatment for multiple myeloma, particularly in cases where the cancer has relapsed or become refractory to other treatments. The descriptions provided suggest that this combination therapy is used to treat multiple myeloma in general, without specifying any particular stage or subtype of the disease.

In summary, POMALIDOMIDE and DEXAMETHASONE are used together as a treatment for multiple myeloma, a type of blood cancer. The combination of these two medications has been shown to be effective in treating relapsed and refractory multiple myeloma, where the cancer has returned or become resistant to other treatments. By using pomalidomide and dexamethasone together, healthcare providers can help to manage the symptoms of multiple myeloma and improve outcomes for patients with this challenging disease.</data>
    </edge>
    <edge id="e14" source="1" target="15">
      <data key="d3">24.0</data>
      <data key="d4">two related pharmaceutical...</data>
      <data key="d6">Pomalidomide and Lenalidomide are two related pharmaceutical drugs that have been used in the treatment of various medical conditions.

Lenalidomide is a medication that has been used to treat multiple myeloma, a type of blood cancer. It works by modulating the immune system and inhibiting the growth of cancer cells. Patients who have received lenalidomide prior to being treated with pomalidomide have been the focus of some studies.

Pomalidomide is another medication that has also been used to treat multiple myeloma, particularly in patients who have become refractory, or resistant, to lenalidomide. Pomalidomide is often used in combination with dexamethasone, a corticosteroid, to enhance its effectiveness.

The provided descriptions indicate that the patients who were treated with pomalidomide had previously received lenalidomide, and were refractory to it prior to receiving the pomalidomide plus dexamethasone treatment. This suggests that pomalidomide may be a viable option for patients who have become resistant to lenalidomide, providing an alternative treatment approach.

It is important to note that the use of these medications, particularly in combination, may be complex and require careful consideration by healthcare professionals. The specific dosages, timing, and monitoring of these treatments can be crucial to ensuring the best possible outcomes for patients.

In summary, pomalidomide and lenalidomide are two related medications that have been used in the treatment of multiple myeloma. Patients who have received lenalidomide and become refractory to it may be candidates for treatment with pomalidomide, often in combination with dexamethasone, as an alternative approach to managing their condition.</data>
    </edge>
    <edge id="e15" source="1" target="16">
      <data key="d3">15.0</data>
      <data key="d4">two pharmaceutical drugs...</data>
      <data key="d6">Pomalidomide and Bortezomib are two pharmaceutical drugs that have been used in the treatment of various medical conditions.

Pomalidomide is a medication that has been approved for the treatment of multiple myeloma, a type of blood cancer. It is typically used in combination with other drugs, such as dexamethasone, to help manage the symptoms of the disease and improve patient outcomes.

Bortezomib, on the other hand, is a proteasome inhibitor that has also been approved for the treatment of multiple myeloma. It works by interfering with the normal function of the proteasome, a complex of enzymes that play a crucial role in the breakdown of proteins within cells.

According to the provided descriptions, the patients who were treated with pomalidomide had previously received bortezomib prior to becoming refractory, or resistant, to lenalidomide, another medication used in the treatment of multiple myeloma. This suggests that the patients had exhausted other treatment options and were then prescribed pomalidomide as a last resort or in an attempt to overcome the resistance to lenalidomide.

The descriptions do not indicate any contradictions or inconsistencies in the information provided. Instead, they suggest that the patients had a history of multiple myeloma and had been treated with a variety of medications, including bortezomib and lenalidomide, before being prescribed pomalidomide.

In summary, pomalidomide and bortezomib are two medications that have been used in the treatment of multiple myeloma. The patients described in the provided information had previously received bortezomib and had become refractory to lenalidomide, leading to the use of pomalidomide as a subsequent treatment option.</data>
    </edge>
    <edge id="e16" source="1" target="12">
      <data key="d3">9.0</data>
      <data key="d4">Agency assessed reported...</data>
      <data key="d6">The European Medicines Agency assessed and reported on the drug pomalidomide</data>
    </edge>
    <edge id="e17" source="1" target="17">
      <data key="d3">8.0</data>
      <data key="d4">absorption, metabolism excretion...</data>
      <data key="d6">Hoffmann M studied the absorption, metabolism and excretion of pomalidomide in humans</data>
    </edge>
    <edge id="e18" source="1" target="18">
      <data key="d3">8.0</data>
      <data key="d4">drug-drug interaction potential...</data>
      <data key="d6">Kasserra C studied the drug-drug interaction potential of pomalidomide</data>
    </edge>
    <edge id="e19" source="1" target="19">
      <data key="d3">8.0</data>
      <data key="d4">absorption, metabolism excretion...</data>
      <data key="d6">Reyes J studied the absorption, metabolism and excretion of pomalidomide in humans</data>
    </edge>
    <edge id="e20" source="1" target="20">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide alone combination...</data>
      <data key="d6">Matsue K studied pomalidomide alone or in combination with dexamethasone in Japanese patients with multiple myeloma</data>
    </edge>
    <edge id="e21" source="1" target="21">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide alone combination...</data>
      <data key="d6">Iwasaki H studied pomalidomide alone or in combination with dexamethasone in Japanese patients with multiple myeloma</data>
    </edge>
    <edge id="e22" source="1" target="22">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide alone combination...</data>
      <data key="d6">Chou T studied pomalidomide alone or in combination with dexamethasone in Japanese patients with multiple myeloma</data>
    </edge>
    <edge id="e23" source="1" target="23">
      <data key="d3">24.0</data>
      <data key="d4">POMALIDOMIDE drug...</data>
      <data key="d6">POMALIDOMIDE and RICHARDSON PG

POMALIDOMIDE is a drug that has been studied by RICHARDSON PG for the treatment of relapsed and refractory multiple myeloma. Multiple myeloma is a type of blood cancer that affects plasma cells, a type of white blood cell.

RICHARDSON PG, a researcher, has published several studies on the use of POMALIDOMIDE, either alone or in combination with low-dose dexamethasone, for the treatment of relapsed and refractory multiple myeloma. Relapsed multiple myeloma refers to the return of the disease after a period of improvement, while refractory multiple myeloma refers to the disease not responding to treatment.

The studies conducted by RICHARDSON PG have focused on evaluating the efficacy and safety of POMALIDOMIDE in this patient population. POMALIDOMIDE is an immunomodulatory drug that has been shown to have anti-tumor and anti-angiogenic properties, making it a potential treatment option for multiple myeloma.

In one study, RICHARDSON PG and colleagues investigated the use of POMALIDOMIDE and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma. The results of this study demonstrated that this combination therapy was effective in improving patient outcomes, with a significant proportion of patients achieving a response to the treatment.

In another study, RICHARDSON PG examined the use of POMALIDOMIDE alone in the treatment of relapsed multiple myeloma. The findings of this study suggest that POMALIDOMIDE can be an effective treatment option for patients with relapsed disease, even in those who have previously received other therapies.

Overall, the research conducted by RICHARDSON PG on the use of POMALIDOMIDE in the treatment of relapsed and refractory multiple myeloma has contributed to a better understanding of the potential therapeutic benefits of this drug. The studies have provided valuable insights into the efficacy and safety of POMALIDOMIDE, either alone or in combination with other therapies, in this patient population.

The comprehensive summary of the data provided indicates that RICHARDSON PG has conducted multiple studies on the use of POMALIDOMIDE in the treatment of relapsed and refractory multiple myeloma. The findings from these studies suggest that POMALIDOMIDE, either alone or in combination with low-dose dexamethasone, can be an effective treatment option for patients with this type of blood cancer.</data>
    </edge>
    <edge id="e24" source="1" target="24">
      <data key="d3">17.0</data>
      <data key="d4">DS's Research Relapsed...</data>
      <data key="d6">Pomalidomide and Siegel DS's Research on Relapsed and Refractory Multiple Myeloma

Pomalidomide is a medication that has been studied for the treatment of relapsed and refractory multiple myeloma, a type of blood cancer. Dr. David S. Siegel, a prominent researcher in the field of multiple myeloma, has published research on the use of pomalidomide, both alone and in combination with low-dose dexamethasone, in patients with relapsed and refractory multiple myeloma.

According to the provided descriptions, Siegel DS has conducted research on the use of pomalidomide and low-dose dexamethasone in the treatment of relapsed and refractory multiple myeloma. The research indicates that Siegel DS studied the use of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma.

The descriptions suggest that Siegel DS's research focused on evaluating the efficacy and safety of pomalidomide, either as a standalone treatment or in combination with low-dose dexamethasone, for patients with multiple myeloma that has relapsed or become refractory to previous treatments. Relapsed multiple myeloma refers to the disease returning after a period of remission, while refractory multiple myeloma indicates that the disease has not responded to previous treatments.

By studying the use of pomalidomide in this patient population, Siegel DS aimed to provide insights into the potential therapeutic benefits of this medication for individuals with advanced, difficult-to-treat multiple myeloma. The research findings from Siegel DS's work may have contributed to the understanding of the role of pomalidomide in the management of relapsed and refractory multiple myeloma, potentially informing clinical practice and guiding future treatment approaches for this challenging disease.

In summary, Siegel DS has conducted research on the use of pomalidomide, both alone and in combination with low-dose dexamethasone, in the treatment of relapsed and refractory multiple myeloma. The research findings from Siegel DS's work may have contributed to the understanding of the potential therapeutic benefits of pomalidomide for patients with advanced multiple myeloma who have limited treatment options.</data>
    </edge>
    <edge id="e25" source="1" target="25">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide alone combination...</data>
      <data key="d6">Vij R studied pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma</data>
    </edge>
    <edge id="e26" source="1" target="26">
      <data key="d3">16.0</data>
      <data key="d4">MIGUEL POMALIDOMIDE...</data>
      <data key="d6">POMALIDOMIDE and SAN MIGUEL J

POMALIDOMIDE is a medication used in the treatment of relapsed and refractory multiple myeloma, a type of blood cancer. SAN MIGUEL J is a researcher who has conducted studies on the use of POMALIDOMIDE in this context.

According to the provided descriptions, SAN MIGUEL J published research comparing the use of POMALIDOMIDE plus low-dose dexamethasone (a corticosteroid) versus the use of high-dose dexamethasone alone in patients with relapsed and refractory multiple myeloma. The research aimed to evaluate the efficacy and safety of these two treatment approaches in this patient population.

Multiple myeloma is a cancer that affects the plasma cells, a type of white blood cell responsible for producing antibodies. In relapsed and refractory multiple myeloma, the disease has returned or continued to progress despite previous treatments. The use of POMALIDOMIDE, an immunomodulatory drug, in combination with low-dose dexamethasone, represents a potential treatment option for these patients.

The research conducted by SAN MIGUEL J compared the outcomes of patients treated with POMALIDOMIDE plus low-dose dexamethasone versus those treated with high-dose dexamethasone alone. The study likely evaluated parameters such as overall response rates, progression-free survival, and safety profiles of the two treatment regimens.

The findings of this research may provide valuable insights into the efficacy and tolerability of POMALIDOMIDE-based therapy in the management of relapsed and refractory multiple myeloma. This information can help healthcare providers make informed decisions when selecting the most appropriate treatment approach for their patients with this challenging form of the disease.

In summary, SAN MIGUEL J has conducted research on the use of POMALIDOMIDE, an immunomodulatory drug, in combination with low-dose dexamethasone, compared to high-dose dexamethasone alone, in the treatment of relapsed and refractory multiple myeloma. The results of this research may contribute to the understanding of effective treatment strategies for patients with this form of blood cancer.</data>
    </edge>
    <edge id="e27" source="1" target="27">
      <data key="d3">16.0</data>
      <data key="d4">medication used treatment...</data>
      <data key="d6">Pomalidomide is a medication used in the treatment of relapsed and refractory multiple myeloma. Weisel K, a researcher, has published studies on the use of pomalidomide in this context.

Weisel K's research has focused on the use of pomalidomide, often in combination with low-dose dexamethasone, for the treatment of multiple myeloma patients who have relapsed or become refractory to other therapies. Multiple myeloma is a type of blood cancer that affects plasma cells, a type of white blood cell. Relapsed and refractory multiple myeloma refers to cases where the cancer has returned or become resistant to standard treatments.

Pomalidomide is an immunomodulatory drug that works by modulating the immune system and inhibiting the growth and survival of myeloma cells. Weisel K's studies have explored the efficacy and safety of using pomalidomide, either alone or in combination with low-dose dexamethasone, in patients with relapsed and refractory multiple myeloma.

The studies conducted by Weisel K have provided valuable insights into the potential benefits of pomalidomide-based regimens for this patient population. The findings suggest that pomalidomide, particularly when used in combination with low-dose dexamethasone, can be an effective treatment option for individuals with multiple myeloma that has relapsed or become resistant to other therapies.

Overall, Weisel K's research has contributed to the understanding of the role of pomalidomide in the management of relapsed and refractory multiple myeloma. The comprehensive summary of the data provided indicates that Weisel K's work has focused on exploring the use of this medication, either alone or in combination with other therapies, to improve outcomes for patients with this challenging form of blood cancer.</data>
    </edge>
    <edge id="e28" source="1" target="28">
      <data key="d3">16.0</data>
      <data key="d4">Pomalidomide drug...</data>
      <data key="d6">POMALIDOMIDE and MOREAU P

Pomalidomide is a drug used in the treatment of relapsed and refractory multiple myeloma, a type of blood cancer. Moreau P, a researcher, has conducted studies on the use of pomalidomide in this context.

Moreau P published research comparing the efficacy of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in patients with relapsed and refractory multiple myeloma. The study aimed to evaluate the effectiveness of the combination of pomalidomide and low-dose dexamethasone in this patient population.

Additionally, Moreau P has studied the use of pomalidomide plus low-dose dexamethasone in the treatment of relapsed and refractory multiple myeloma. This research focused on the potential benefits of the pomalidomide and low-dose dexamethasone combination in managing this challenging form of multiple myeloma.

The studies conducted by Moreau P provide valuable insights into the role of pomalidomide in the management of relapsed and refractory multiple myeloma. The findings suggest that the combination of pomalidomide and low-dose dexamethasone may be a promising treatment approach for patients with this condition, potentially offering improved outcomes compared to high-dose dexamethasone alone.

By synthesizing the information from the provided descriptions, it appears that Moreau P's research has focused on evaluating the efficacy and potential benefits of using pomalidomide, either alone or in combination with low-dose dexamethasone, in the treatment of relapsed and refractory multiple myeloma. The studies aim to provide healthcare professionals with evidence-based guidance on the use of pomalidomide in this clinical setting.

In summary, the research conducted by Moreau P has explored the role of pomalidomide, both as a standalone therapy and in combination with low-dose dexamethasone, in the management of relapsed and refractory multiple myeloma. The findings from these studies may contribute to the development of more effective treatment strategies for patients with this challenging form of blood cancer.</data>
    </edge>
    <edge id="e29" source="1" target="29">
      <data key="d3">16.0</data>
      <data key="d4">Pomalidomide medication...</data>
      <data key="d6">Pomalidomide and Dimopoulos MA

Pomalidomide is a medication used in the treatment of relapsed and refractory multiple myeloma. Dimopoulos MA, a prominent researcher in the field of multiple myeloma, has published studies examining the use of pomalidomide in this context.

Dimopoulos MA's research has focused on evaluating the safety and efficacy of pomalidomide, often in combination with low-dose dexamethasone, for patients with refractory multiple myeloma. Refractory multiple myeloma refers to a form of the disease that has become resistant to standard treatments, making it particularly challenging to manage.

Through his studies, Dimopoulos MA has provided valuable insights into the potential benefits of pomalidomide for this patient population. The research has explored the ability of pomalidomide, either alone or in combination with dexamethasone, to improve outcomes for individuals with relapsed and refractory multiple myeloma.

Multiple myeloma is a type of blood cancer that affects plasma cells, a specialized type of white blood cell. In relapsed and refractory multiple myeloma, the disease has returned or persisted despite previous treatments, making it a significant challenge for healthcare providers and patients alike.

Dimopoulos MA's work has contributed to the understanding of pomalidomide's role in the management of this complex and often difficult-to-treat form of multiple myeloma. By examining the safety and efficacy of pomalidomide, Dimopoulos MA's research has helped to inform clinical decision-making and improve the care available to patients with relapsed and refractory multiple myeloma.

Overall, the research conducted by Dimopoulos MA on the use of pomalidomide in relapsed and refractory multiple myeloma has been instrumental in advancing the understanding and treatment of this challenging disease. His findings have the potential to positively impact the lives of patients facing this difficult diagnosis.</data>
    </edge>
    <edge id="e30" source="1" target="30">
      <data key="d3">8.0</data>
      <data key="d4">impact age...</data>
      <data key="d6">Palumbo A studied the impact of age on outcomes in patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone</data>
    </edge>
    <edge id="e31" source="1" target="31">
      <data key="d3">8.0</data>
      <data key="d4">safety efficacy...</data>
      <data key="d6">Corradini P studied the safety and efficacy of pomalidomide plus low-dose dexamethasone in refractory multiple myeloma</data>
    </edge>
    <edge id="e32" source="1" target="32">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide plus dexamethasone...</data>
      <data key="d6">Ichinohe T studied pomalidomide plus dexamethasone in Japanese patients with relapsed and refractory multiple myeloma</data>
    </edge>
    <edge id="e33" source="1" target="33">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide plus dexamethasone...</data>
      <data key="d6">Kuroda Y studied pomalidomide plus dexamethasone in Japanese patients with relapsed and refractory multiple myeloma</data>
    </edge>
    <edge id="e34" source="1" target="34">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide plus dexamethasone...</data>
      <data key="d6">Okamoto S studied pomalidomide plus dexamethasone in Japanese patients with relapsed and refractory multiple myeloma</data>
    </edge>
    <edge id="e35" source="1" target="35">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide plus dexamethasone...</data>
      <data key="d6">Chng WJ studied pomalidomide plus dexamethasone in Asian patients with relapsed/refractory myeloma</data>
    </edge>
    <edge id="e36" source="1" target="36">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide plus dexamethasone...</data>
      <data key="d6">Kim K studied pomalidomide plus dexamethasone in Asian patients with relapsed/refractory myeloma</data>
    </edge>
    <edge id="e37" source="1" target="37">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide plus dexamethasone...</data>
      <data key="d6">Huang J studied pomalidomide plus dexamethasone in Asian patients with relapsed/refractory myeloma</data>
    </edge>
    <edge id="e38" source="1" target="13">
      <data key="d3">44.0</data>
      <data key="d4">drug used treat...</data>
      <data key="d6">Pomalidomide is a drug used to treat multiple myeloma, a type of blood cancer. Multiple myeloma is a cancer that affects plasma cells, a type of white blood cell that produces antibodies. Pomalidomide is an immunomodulatory agent, which means it helps the immune system fight the cancer.

Pomalidomide is specifically used to treat relapsed or refractory multiple myeloma. Relapsed myeloma means the cancer has returned after a period of remission, while refractory myeloma means the cancer has not responded to previous treatments. Pomalidomide is considered a new treatment option for these patients who have exhausted other therapies.

The descriptions provided indicate that pomalidomide is an effective treatment for multiple myeloma, regardless of whether the cancer has relapsed or is refractory to other treatments. Pomalidomide helps the immune system recognize and attack the myeloma cells, leading to improved outcomes for patients.

In summary, pomalidomide is a drug used to treat multiple myeloma, a type of blood cancer. It is particularly effective for patients with relapsed or refractory myeloma, who have not responded to other treatments. Pomalidomide is a new immunomodulatory agent that helps the immune system fight the cancer, leading to better outcomes for patients with this serious and often difficult-to-treat condition.</data>
    </edge>
    <edge id="e39" source="16" target="13">
      <data key="d3">8.0</data>
      <data key="d4">myeloma been previously...</data>
      <data key="d6">Patients with relapsed/refractory myeloma had been previously treated with bortezomib</data>
    </edge>
    <edge id="e40" source="15" target="13">
      <data key="d3">9.0</data>
      <data key="d4">medication used treatment...</data>
      <data key="d6">Lenalidomide is a medication used in the treatment of multiple myeloma, a type of blood cancer. Multiple myeloma is a condition characterized by the abnormal growth and accumulation of plasma cells, a type of white blood cell, in the bone marrow.

Lenalidomide is primarily used in the treatment of relapsed or refractory multiple myeloma. Relapsed myeloma refers to a situation where the disease has returned after a period of remission, while refractory myeloma indicates that the disease has not responded to previous treatments.

The provided descriptions suggest that lenalidomide is an effective treatment option for patients with relapsed or refractory multiple myeloma. However, there appears to be a contradiction in the information, as one description states that patients with relapsed/refractory myeloma were refractory to lenalidomide.

To resolve this contradiction, it is important to note that while lenalidomide is generally effective in the treatment of relapsed or refractory multiple myeloma, there may be some patients who do not respond to this medication. This could be due to various factors, such as the specific characteristics of the patient's disease, the stage of the disease, or the presence of other underlying health conditions.

In summary, lenalidomide is a medication used in the treatment of multiple myeloma, particularly in cases of relapsed or refractory disease. While it is generally an effective treatment option, there may be some patients who do not respond to lenalidomide, and their disease may be considered refractory to this medication.</data>
    </edge>
    <edge id="e41" source="1" target="41">
      <data key="d3">16.0</data>
      <data key="d4">Network conducted trial...</data>
      <data key="d6">The Asian Myeloma Network conducted a trial on the use of pomalidomide plus dexamethasone in Asian patients with relapsed/refractory multiple myeloma</data>
    </edge>
    <edge id="e42" source="1" target="38">
      <data key="d3">25.0</data>
      <data key="d4">Impairment Celgene Corporation...</data>
      <data key="d6">Pomalidomide and Renal Impairment

Celgene Corporation has studied the use of pomalidomide, a drug used to treat multiple myeloma, in patients with renal impairment. Multiple myeloma is a type of blood cancer that affects the plasma cells in the bone marrow, and renal impairment is a condition where the kidneys are not functioning properly.

The studies conducted by Celgene Corporation have found that pomalidomide, when combined with dexamethasone, a corticosteroid, can be an effective treatment for multiple myeloma patients with renal impairment. Pomalidomide is a derivative of thalidomide and has been approved for the treatment of multiple myeloma patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.

The combination of pomalidomide and dexamethasone has been shown to be effective in improving the outcomes of multiple myeloma patients with renal impairment. Renal impairment is a common complication of multiple myeloma, as the abnormal plasma cells can produce proteins that can damage the kidneys. By using pomalidomide, which has been shown to be effective in patients with renal impairment, Celgene Corporation has provided a treatment option for this patient population.

The studies conducted by Celgene Corporation have demonstrated that pomalidomide plus dexamethasone can be a viable treatment option for multiple myeloma patients with renal impairment. This is an important finding, as these patients often have limited treatment options and may experience poorer outcomes compared to those without renal impairment. The use of pomalidomide in this patient population can help to improve their overall prognosis and quality of life.

In summary, Celgene Corporation has studied the use of pomalidomide in multiple myeloma patients with renal impairment and found that the combination of pomalidomide and dexamethasone can be an effective treatment option for this patient population. This is a significant development in the management of multiple myeloma, as it provides a new treatment option for patients with this challenging complication.</data>
    </edge>
    <edge id="e43" source="13" target="42">
      <data key="d3">2.0</data>
      <data key="d4">drug used treatment...</data>
      <data key="d6">Daratumumab is a drug used in the treatment of multiple myeloma</data>
    </edge>
    <edge id="e44" source="1" target="43">
      <data key="d3">1.0</data>
      <data key="d4">active ingredient drug...</data>
      <data key="d6">Pomalidomide is the active ingredient in the drug Imnovid®</data>
    </edge>
    <edge id="e45" source="1" target="44">
      <data key="d3">10.0</data>
      <data key="d4">must participate pregnancy...</data>
      <data key="d6">Patients taking pomalidomide must participate in a pregnancy prevention program to avoid pregnancy during and after treatment.</data>
    </edge>
    <edge id="e46" source="1" target="45">
      <data key="d3">1.0</data>
      <data key="d4">must use effective...</data>
      <data key="d6">Patients taking pomalidomide must use effective contraception to prevent pregnancy during and after treatment.</data>
    </edge>
    <edge id="e47" source="1" target="46">
      <data key="d3">9.0</data>
      <data key="d4">will discuss pomalidomide...</data>
      <data key="d6">The cancer team will discuss the pomalidomide treatment and its side effects with the patient.</data>
    </edge>
    <edge id="e48" source="1" target="47">
      <data key="d3">8.0</data>
      <data key="d4">will have regular...</data>
      <data key="d6">Patients taking pomalidomide will have regular blood tests to monitor their treatment.</data>
    </edge>
    <edge id="e49" source="1" target="48">
      <data key="d3">8.0</data>
      <data key="d4">course several...</data>
      <data key="d6">Pomalidomide is given in a course of several treatment cycles, with each cycle having days of treatment and rest days.</data>
    </edge>
    <edge id="e50" source="1" target="49">
      <data key="d3">1.0</data>
      <data key="d4">may also given...</data>
      <data key="d6">Patients taking pomalidomide may also be given anti-sickness drugs to take home.</data>
    </edge>
    <edge id="e51" source="1" target="50">
      <data key="d3">8.0</data>
      <data key="d4">mood changes that...</data>
      <data key="d6">Pomalidomide can cause mood changes that should be reported to the doctor</data>
    </edge>
    <edge id="e52" source="1" target="51">
      <data key="d3">8.0</data>
      <data key="d4">blurry vision side...</data>
      <data key="d6">Pomalidomide can cause blurry vision as a side effect</data>
    </edge>
    <edge id="e53" source="1" target="52">
      <data key="d3">8.0</data>
      <data key="d4">cataracts side effect...</data>
      <data key="d6">Pomalidomide can cause cataracts as a side effect</data>
    </edge>
    <edge id="e54" source="1" target="53">
      <data key="d3">9.0</data>
      <data key="d4">donate blood during...</data>
      <data key="d6">You must not donate blood during or for 1 week after taking pomalidomide</data>
    </edge>
    <edge id="e55" source="1" target="54">
      <data key="d3">9.0</data>
      <data key="d4">with other medicines,...</data>
      <data key="d6">Pomalidomide can interact with other medicines, so you should tell your doctor about any other drugs you are taking</data>
    </edge>
    <edge id="e56" source="1" target="55">
      <data key="d3">9.0</data>
      <data key="d4">breastfeed while taking...</data>
      <data key="d6">You should not breastfeed while taking pomalidomide or for some time after treatment ends</data>
    </edge>
    <edge id="e57" source="1" target="56">
      <data key="d3">1.0</data>
      <data key="d4">fertility, you should...</data>
      <data key="d6">Pomalidomide can affect fertility, so you should discuss this with your doctor before starting treatment</data>
    </edge>
    <edge id="e58" source="13" target="62">
      <data key="d3">8.0</data>
      <data key="d4">Standards Haematology provided...</data>
      <data key="d6">The British Committee for Standards in Haematology provided guidelines for the diagnosis and management of multiple myeloma</data>
    </edge>
    <edge id="e59" source="13" target="63">
      <data key="d3">8.0</data>
      <data key="d4">Forum provided guidelines...</data>
      <data key="d6">The UK Myeloma Forum provided guidelines for the diagnosis and management of multiple myeloma</data>
    </edge>
    <edge id="e60" source="13" target="39">
      <data key="d3">8.0</data>
      <data key="d4">Cancer Network provided...</data>
      <data key="d6">The National Comprehensive Cancer Network provided clinical practice guidelines for the treatment of multiple myeloma</data>
    </edge>
    <edge id="e61" source="13" target="40">
      <data key="d3">8.0</data>
      <data key="d4">Medical Oncology provided...</data>
      <data key="d6">The European Society for Medical Oncology provided clinical practice guidelines for the diagnosis, treatment and follow-up of multiple myeloma</data>
    </edge>
    <edge id="e62" source="13" target="64">
      <data key="d3">8.0</data>
      <data key="d4">End Results Program...</data>
      <data key="d6">The Surveillance, Epidemiology, and End Results Program provides cancer statistics on multiple myeloma</data>
    </edge>
    <edge id="e63" source="15" target="1">
      <data key="d3">8.0</data>
      <data key="d4">patients who have...</data>
      <data key="d6">Pomalidomide is used in patients who have received at least two prior therapies, including lenalidomide</data>
    </edge>
    <edge id="e64" source="16" target="1">
      <data key="d3">8.0</data>
      <data key="d4">patients who have...</data>
      <data key="d6">Pomalidomide is used in patients who have received at least two prior therapies, including bortezomib</data>
    </edge>
    <edge id="e65" source="57" target="1">
      <data key="d3">9.0</data>
      <data key="d4">evaluated efficacy safety...</data>
      <data key="d6">The MM-002 trial evaluated the efficacy and safety of pomalidomide plus low-dose dexamethasone</data>
    </edge>
    <edge id="e66" source="58" target="1">
      <data key="d3">1.0</data>
      <data key="d4">evaluated efficacy safety...</data>
      <data key="d6">The MM-003 trial evaluated the efficacy and safety of pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone</data>
    </edge>
    <edge id="e67" source="14" target="1">
      <data key="d3">10.0</data>
      <data key="d4">combination with low-dose...</data>
      <data key="d6">Pomalidomide is used in combination with low-dose dexamethasone to treat multiple myeloma</data>
    </edge>
    <edge id="e68" source="1" target="65">
      <data key="d3">9.0</data>
      <data key="d4">published review...</data>
      <data key="d6">Adis Drug Evaluation published a review on the use of pomalidomide in patients with recurrent multiple myeloma</data>
    </edge>
    <edge id="e69" source="1" target="59">
      <data key="d3">9.0</data>
      <data key="d4">authored review...</data>
      <data key="d6">Lesley J. Scott authored the review on the use of pomalidomide in patients with recurrent multiple myeloma</data>
    </edge>
    <edge id="e70" source="1" target="60">
      <data key="d3">8.0</data>
      <data key="d4">brand name pomalidomide...</data>
      <data key="d6">Imnovid is the brand name for pomalidomide in the EU</data>
    </edge>
    <edge id="e71" source="1" target="61">
      <data key="d3">17.0</data>
      <data key="d4">brand name Pomalyst,...</data>
      <data key="d6">Pomalidomide, also known by the brand name Pomalyst, is a medication used to treat certain types of multiple myeloma, a type of blood cancer. Pomalidomide is the active ingredient in the drug Pomalyst, which is the brand name for pomalidomide in the United States.

Pomalidomide belongs to a class of drugs called immunomodulatory agents, which work by modulating the immune system to help fight cancer. It is typically used in combination with other medications, such as dexamethasone, to treat multiple myeloma in patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.

Pomalidomide has been shown to be effective in treating multiple myeloma by inhibiting the growth and survival of myeloma cells, as well as by stimulating the immune system to attack the cancer cells. It has also been found to have anti-angiogenic properties, meaning it can help prevent the formation of new blood vessels that feed the tumor.

The use of Pomalyst (pomalidomide) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma in adults who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and whose disease has progressed on or within 60 days of completion of the last therapy.

Pomalidomide is typically taken orally, either with or without food, and the dosage and frequency of administration will depend on the individual patient's needs and response to treatment. As with any medication, there are potential side effects associated with the use of pomalidomide, and patients should discuss these with their healthcare providers.

In summary, pomalidomide, marketed under the brand name Pomalyst, is a medication used to treat certain types of multiple myeloma. It is an immunomodulatory agent that has been shown to be effective in inhibiting the growth and survival of myeloma cells, as well as in stimulating the immune system to attack the cancer cells. The use of Pomalyst is approved by the FDA for the treatment of multiple myeloma in adults who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.</data>
    </edge>
    <edge id="e72" source="15" target="67">
      <data key="d3">9.0</data>
      <data key="d4">required antimyeloma activity...</data>
      <data key="d6">Cereblon expression is required for the antimyeloma activity of lenalidomide</data>
    </edge>
    <edge id="e73" source="1" target="67">
      <data key="d3">9.0</data>
      <data key="d4">required antimyeloma activity...</data>
      <data key="d6">Cereblon expression is required for the antimyeloma activity of pomalidomide</data>
    </edge>
    <edge id="e74" source="68" target="13">
      <data key="d3">7.0</data>
      <data key="d4">immunomodulatory thalidomide analog...</data>
      <data key="d6">CC-4047 is an immunomodulatory thalidomide analog that has been studied in relapsed or refractory multiple myeloma</data>
    </edge>
    <edge id="e75" source="1" target="79">
      <data key="d3">9.0</data>
      <data key="d4">drug pomalidomide...</data>
      <data key="d6">Celegene Corporation developed the drug pomalidomide for the treatment of relapsed/refractory multiple myeloma</data>
    </edge>
    <edge id="e76" source="1" target="69">
      <data key="d3">8.0</data>
      <data key="d4">research use...</data>
      <data key="d6">Vij R published research on the use of pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma</data>
    </edge>
    <edge id="e77" source="1" target="70">
      <data key="d3">8.0</data>
      <data key="d4">studies use...</data>
      <data key="d6">Song KW published studies on the use of pomalidomide in relapsed and refractory multiple myeloma</data>
    </edge>
    <edge id="e78" source="1" target="71">
      <data key="d3">8.0</data>
      <data key="d4">studies use...</data>
      <data key="d6">Leleu X published studies on the use of pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma</data>
    </edge>
    <edge id="e79" source="1" target="72">
      <data key="d3">8.0</data>
      <data key="d4">study use...</data>
      <data key="d6">Attal M published a study on the use of pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma</data>
    </edge>
    <edge id="e80" source="1" target="73">
      <data key="d3">8.0</data>
      <data key="d4">study use...</data>
      <data key="d6">Arnulf B published a study on the use of pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma</data>
    </edge>
    <edge id="e81" source="1" target="74">
      <data key="d3">8.0</data>
      <data key="d4">study use...</data>
      <data key="d6">Marco M published a study on the use of pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma with certain genetic abnormalities</data>
    </edge>
    <edge id="e82" source="1" target="75">
      <data key="d3">8.0</data>
      <data key="d4">study use...</data>
      <data key="d6">Karlin L published a study on the use of pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma with certain genetic abnormalities</data>
    </edge>
    <edge id="e83" source="1" target="58">
      <data key="d3">9.0</data>
      <data key="d4">clinical trial studying...</data>
      <data key="d6">MM-003 was a clinical trial studying the use of pomalidomide in relapsed/refractory multiple myeloma</data>
    </edge>
    <edge id="e84" source="1" target="80">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide registered...</data>
      <data key="d6">A clinical trial on pomalidomide was registered on the EU Clinical Trials Register (Eudra CT)</data>
    </edge>
    <edge id="e85" source="1" target="81">
      <data key="d3">8.0</data>
      <data key="d4">Trials Register website...</data>
      <data key="d6">The EU Clinical Trials Register website hosted information on a clinical trial of pomalidomide</data>
    </edge>
    <edge id="e86" source="1" target="82">
      <data key="d3">8.0</data>
      <data key="d4">use pomalidomide were...</data>
      <data key="d6">Studies on the use of pomalidomide were published in the medical journal Blood</data>
    </edge>
    <edge id="e87" source="1" target="83">
      <data key="d3">8.0</data>
      <data key="d4">use pomalidomide...</data>
      <data key="d6">A study on the use of pomalidomide was published in the medical journal Lancet Oncology</data>
    </edge>
    <edge id="e88" source="1" target="84">
      <data key="d3">1.0</data>
      <data key="d4">use pomalidomide were...</data>
      <data key="d6">Multiple studies on the use of pomalidomide were presented at the American Society of Hematology annual meeting</data>
    </edge>
    <edge id="e89" source="14" target="79">
      <data key="d3">9.0</data>
      <data key="d4">use dexamethasone...</data>
      <data key="d6">Celegene Corporation studied the use of dexamethasone in combination with pomalidomide to treat relapsed/refractory multiple myeloma</data>
    </edge>
    <edge id="e90" source="14" target="13">
      <data key="d3">9.0</data>
      <data key="d4">combination with pomalidomide...</data>
      <data key="d6">Dexamethasone is used in combination with pomalidomide to treat relapsed/refractory multiple myeloma</data>
    </edge>
    <edge id="e91" source="14" target="58">
      <data key="d3">9.0</data>
      <data key="d4">use pomalidomide combination...</data>
      <data key="d6">MM-003 studied the use of pomalidomide in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma</data>
    </edge>
    <edge id="e92" source="13" target="76">
      <data key="d3">15.0</data>
      <data key="d4">Short Multiple myeloma...</data>
      <data key="d6">Multiple Myeloma and Short KD

Multiple myeloma is a type of cancer that affects the plasma cells, a type of white blood cell responsible for producing antibodies. It is characterized by the abnormal proliferation of these plasma cells, leading to the accumulation of malignant cells in the bone marrow.

Short KD, a researcher, has conducted a study on the incidence of extramedullary disease in multiple myeloma patients. Extramedullary disease refers to the presence of myeloma cells outside of the bone marrow, which can occur in a small percentage of multiple myeloma cases.

The study published by Short KD examined the incidence of extramedullary disease in multiple myeloma patients. Extramedullary disease can be a challenging complication of multiple myeloma, as it can lead to the development of tumors in various organs and tissues outside of the bone marrow. Understanding the prevalence of this condition is important for the management and treatment of multiple myeloma patients.

The findings of Short KD's study provide valuable insights into the incidence of extramedullary disease in multiple myeloma. By analyzing data from multiple myeloma patients, the study aimed to shed light on the frequency and patterns of this complication. The results of the study can help healthcare professionals better understand the risk factors and clinical implications of extramedullary disease in multiple myeloma, ultimately leading to improved patient care and outcomes.

In summary, Multiple Myeloma is a type of cancer that affects the plasma cells, and Short KD has conducted a study on the incidence of extramedullary disease in multiple myeloma patients. The study's findings contribute to the understanding of this complication and its impact on the management and treatment of multiple myeloma.</data>
    </edge>
    <edge id="e93" source="13" target="77">
      <data key="d3">15.0</data>
      <data key="d4">Rajkumar Multiple myeloma...</data>
      <data key="d6">Multiple Myeloma and Rajkumar SV

Multiple myeloma is a type of blood cancer that affects plasma cells, a type of white blood cell. Rajkumar SV, a renowned hematologist and oncologist, has conducted research on various aspects of multiple myeloma, including the incidence of extramedullary disease in these patients.

Rajkumar SV published a study that examined the incidence of extramedullary disease in multiple myeloma patients. Extramedullary disease refers to the presence of myeloma cells outside of the bone marrow, which can occur in various organs and tissues. The study aimed to investigate the prevalence and clinical implications of this condition in multiple myeloma patients.

Through his research, Rajkumar SV studied the incidence of extramedullary disease in multiple myeloma patients. Extramedullary disease can be a challenging complication in the management of multiple myeloma, as it can lead to organ dysfunction and poor prognosis. Rajkumar SV's work has contributed to a better understanding of this aspect of the disease, which can help healthcare professionals in developing more effective treatment strategies for patients with multiple myeloma.

Rajkumar SV's research on the incidence of extramedullary disease in multiple myeloma patients has been widely recognized and has contributed to the advancement of knowledge in this field. His findings have been published in peer-reviewed journals, and his expertise in the management of multiple myeloma is highly respected within the medical community.

In summary, Rajkumar SV, a leading hematologist and oncologist, has conducted research on the incidence of extramedullary disease in multiple myeloma patients. His work has provided valuable insights into this challenging aspect of the disease, which can help healthcare professionals in improving the care and outcomes for patients with multiple myeloma.</data>
    </edge>
    <edge id="e94" source="13" target="78">
      <data key="d3">8.0</data>
      <data key="d4">Larson Larson...</data>
      <data key="d6">Multiple Myeloma and Larson D

Larson D, a researcher, has conducted a study on the incidence of extramedullary disease in multiple myeloma patients. Multiple myeloma is a type of cancer that affects the plasma cells, a type of white blood cell, and can lead to the development of extramedullary disease, which is the growth of myeloma cells outside of the bone marrow.

Larson D's study focused on investigating the prevalence of extramedullary disease in multiple myeloma patients. The study aimed to provide insights into the clinical characteristics and outcomes of patients with this condition. Multiple myeloma is a complex and heterogeneous disease, and the development of extramedullary disease can have significant implications for patient prognosis and treatment.

The study conducted by Larson D provides valuable information about the incidence of extramedullary disease in multiple myeloma patients. The findings from this research can contribute to a better understanding of the disease and help healthcare professionals develop more effective treatment strategies for patients with multiple myeloma and extramedullary disease.

The comprehensive summary of the data provided indicates that Larson D has published a study on the incidence of extramedullary disease in multiple myeloma patients. The study aimed to investigate the prevalence and characteristics of this condition in the multiple myeloma patient population. The findings from this research can help advance the understanding of multiple myeloma and guide the development of more effective treatment approaches for patients with this complex and challenging disease.</data>
    </edge>
    <edge id="e95" source="13" target="87">
      <data key="d3">8.0</data>
      <data key="d4">treat relapsed refractory...</data>
      <data key="d6">Examethasone is used to treat relapsed or refractory multiple myeloma</data>
    </edge>
    <edge id="e96" source="13" target="85">
      <data key="d3">15.0</data>
      <data key="d4">genetic abnormality associated...</data>
      <data key="d6">Deletion 17p is a genetic abnormality associated with multiple myeloma</data>
    </edge>
    <edge id="e97" source="13" target="86">
      <data key="d3">15.0</data>
      <data key="d4">genetic abnormality associated...</data>
      <data key="d6">Translocation t(4;14) is a genetic abnormality associated with multiple myeloma</data>
    </edge>
    <edge id="e98" source="13" target="16">
      <data key="d3">17.0</data>
      <data key="d4">drug used treatment...</data>
      <data key="d6">Bortezomib is a drug used in the treatment of multiple myeloma</data>
    </edge>
    <edge id="e99" source="13" target="15">
      <data key="d3">17.0</data>
      <data key="d4">drug used treatment...</data>
      <data key="d6">Lenalidomide is a drug used in the treatment of multiple myeloma</data>
    </edge>
    <edge id="e100" source="13" target="102">
      <data key="d3">7.0</data>
      <data key="d4">prognostic factors multiple...</data>
      <data key="d6">Bladé J studied prognostic factors for multiple myeloma</data>
    </edge>
    <edge id="e101" source="13" target="103">
      <data key="d3">7.0</data>
      <data key="d4">prognostic factors multiple...</data>
      <data key="d6">Rosiñol L studied prognostic factors for multiple myeloma</data>
    </edge>
    <edge id="e102" source="13" target="104">
      <data key="d3">7.0</data>
      <data key="d4">prognostic factors multiple...</data>
      <data key="d6">Cibeira MT studied prognostic factors for multiple myeloma</data>
    </edge>
    <edge id="e103" source="1" target="11">
      <data key="d3">10.0</data>
      <data key="d4">drug pomalidomide...</data>
      <data key="d6">Celgene Corporation developed the drug pomalidomide</data>
    </edge>
    <edge id="e104" source="1" target="66">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide treatment...</data>
      <data key="d6">Lacy MQ studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </edge>
    <edge id="e105" source="1" target="88">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide treatment...</data>
      <data key="d6">Kumar SK studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </edge>
    <edge id="e106" source="1" target="89">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide treatment...</data>
      <data key="d6">LaPlant BR studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </edge>
    <edge id="e107" source="1" target="90">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide treatment...</data>
      <data key="d6">Mikhael JR studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </edge>
    <edge id="e108" source="1" target="91">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide treatment...</data>
      <data key="d6">Hayman SR studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </edge>
    <edge id="e109" source="1" target="92">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide treatment...</data>
      <data key="d6">Laumann K studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </edge>
    <edge id="e110" source="1" target="93">
      <data key="d3">7.0</data>
      <data key="d4">pomalidomide treatment...</data>
      <data key="d6">Cooney MM studied pomalidomide in the treatment of solid tumors</data>
    </edge>
    <edge id="e111" source="1" target="94">
      <data key="d3">7.0</data>
      <data key="d4">pomalidomide treatment...</data>
      <data key="d6">Nock C studied pomalidomide in the treatment of solid tumors</data>
    </edge>
    <edge id="e112" source="1" target="95">
      <data key="d3">7.0</data>
      <data key="d4">pomalidomide treatment...</data>
      <data key="d6">Bokar J studied pomalidomide in the treatment of solid tumors</data>
    </edge>
    <edge id="e113" source="1" target="96">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide treatment...</data>
      <data key="d6">Siegel D studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </edge>
    <edge id="e114" source="1" target="97">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide treatment...</data>
      <data key="d6">Allred JB studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </edge>
    <edge id="e115" source="1" target="98">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide treatment...</data>
      <data key="d6">Gertz MA studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </edge>
    <edge id="e116" source="1" target="99">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide treatment...</data>
      <data key="d6">Jagannath S studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </edge>
    <edge id="e117" source="1" target="100">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide treatment...</data>
      <data key="d6">Hofmeister CC studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </edge>
    <edge id="e118" source="1" target="101">
      <data key="d3">8.0</data>
      <data key="d4">pomalidomide treatment...</data>
      <data key="d6">Baz RC studied pomalidomide in the treatment of relapsed multiple myeloma</data>
    </edge>
    <edge id="e119" source="1" target="105">
      <data key="d3">1.0</data>
      <data key="d4">pomalidomide combination with...</data>
      <data key="d6">Roy V studied pomalidomide in combination with bortezomib and dexamethasone for relapsed multiple myeloma</data>
    </edge>
    <edge id="e120" source="23" target="84">
      <data key="d3">8.0</data>
      <data key="d4">research American Society...</data>
      <data key="d6">Richardson PG presented research at the American Society of Hematology meeting</data>
    </edge>
    <edge id="e121" source="23" target="1">
      <data key="d3">8.0</data>
      <data key="d4">phase trial...</data>
      <data key="d6">Pomalidomide was studied in a phase I trial presented by Richardson PG</data>
    </edge>
    <edge id="e122" source="23" target="16">
      <data key="d3">8.0</data>
      <data key="d4">phase trial...</data>
      <data key="d6">Bortezomib was studied in a phase I trial presented by Richardson PG</data>
    </edge>
    <edge id="e123" source="23" target="14">
      <data key="d3">8.0</data>
      <data key="d4">phase trial...</data>
      <data key="d6">Dexamethasone was studied in a phase I trial presented by Richardson PG</data>
    </edge>
    <edge id="e124" source="100" target="84">
      <data key="d3">8.0</data>
      <data key="d4">research American Society...</data>
      <data key="d6">Hofmeister CC presented research at the American Society of Hematology meeting</data>
    </edge>
    <edge id="e125" source="100" target="1">
      <data key="d3">8.0</data>
      <data key="d4">phase trial...</data>
      <data key="d6">Pomalidomide was studied in a phase I trial presented by Hofmeister CC</data>
    </edge>
    <edge id="e126" source="96" target="84">
      <data key="d3">8.0</data>
      <data key="d4">research American Society...</data>
      <data key="d6">Siegel D presented research at the American Society of Hematology meeting</data>
    </edge>
    <edge id="e127" source="96" target="1">
      <data key="d3">8.0</data>
      <data key="d4">phase trial...</data>
      <data key="d6">Pomalidomide was studied in a phase I trial presented by Siegel D</data>
    </edge>
    <edge id="e128" source="106" target="84">
      <data key="d3">8.0</data>
      <data key="d4">research American Society...</data>
      <data key="d6">Stadtmauer EA presented research at the American Society of Hematology meeting</data>
    </edge>
    <edge id="e129" source="106" target="1">
      <data key="d3">8.0</data>
      <data key="d4">phase I/II dose...</data>
      <data key="d6">Pomalidomide was studied in a phase I/II dose expansion trial presented by Stadtmauer EA</data>
    </edge>
    <edge id="e130" source="107" target="84">
      <data key="d3">8.0</data>
      <data key="d4">research American Society...</data>
      <data key="d6">Abonour R presented research at the American Society of Hematology meeting</data>
    </edge>
    <edge id="e131" source="107" target="1">
      <data key="d3">8.0</data>
      <data key="d4">phase I/II dose...</data>
      <data key="d6">Pomalidomide was studied in a phase I/II dose expansion trial presented by Abonour R</data>
    </edge>
    <edge id="e132" source="108" target="84">
      <data key="d3">8.0</data>
      <data key="d4">research American Society...</data>
      <data key="d6">Martin TG presented research at the American Society of Hematology meeting</data>
    </edge>
    <edge id="e133" source="108" target="1">
      <data key="d3">8.0</data>
      <data key="d4">multicenter randomized phase...</data>
      <data key="d6">Pomalidomide was studied in a multicenter randomized phase II trial presented by Martin TG</data>
    </edge>
    <edge id="e134" source="109" target="84">
      <data key="d3">8.0</data>
      <data key="d4">research American Society...</data>
      <data key="d6">Alsina M presented research at the American Society of Hematology meeting</data>
    </edge>
    <edge id="e135" source="109" target="1">
      <data key="d3">8.0</data>
      <data key="d4">multicenter randomized phase...</data>
      <data key="d6">Pomalidomide was studied in a multicenter randomized phase II trial presented by Alsina M</data>
    </edge>
    <edge id="e136" source="110" target="84">
      <data key="d3">8.0</data>
      <data key="d4">research American Society...</data>
      <data key="d6">Hilger JD presented research at the American Society of Hematology meeting</data>
    </edge>
    <edge id="e137" source="110" target="1">
      <data key="d3">8.0</data>
      <data key="d4">phase trial...</data>
      <data key="d6">Pomalidomide was studied in a phase 1/2 trial presented by Hilger JD</data>
    </edge>
    <edge id="e138" source="111" target="84">
      <data key="d3">8.0</data>
      <data key="d4">research American Society...</data>
      <data key="d6">Klein L presented research at the American Society of Hematology meeting</data>
    </edge>
    <edge id="e139" source="111" target="1">
      <data key="d3">8.0</data>
      <data key="d4">phase trial...</data>
      <data key="d6">Pomalidomide was studied in a phase 1/2 trial presented by Klein L</data>
    </edge>
    <edge id="e140" source="11" target="112">
      <data key="d3">1.0</data>
      <data key="d4">sponsor OPTIMISMM...</data>
      <data key="d6">Celgene Corporation is the sponsor of the OPTIMISMM clinical trial</data>
    </edge>
    <edge id="e141" source="113" target="11">
      <data key="d3">18.0</data>
      <data key="d4">drug POMALYST/IMNOVID...</data>
      <data key="d6">Celgene Corporation developed the drug POMALYST/IMNOVID for the treatment of relapsed or refractory multiple myeloma</data>
    </edge>
    <edge id="e142" source="114" target="11">
      <data key="d3">18.0</data>
      <data key="d4">pivotal Phase III...</data>
      <data key="d6">Celgene Corporation conducted the pivotal Phase III OPTIMISMM study to evaluate the efficacy and safety of POMALYST/IMNOVID</data>
    </edge>
    <edge id="e143" source="61" target="11">
      <data key="d3">20.0</data>
      <data key="d4">drug Pomalyst (pomalidomide)...</data>
      <data key="d6">Celgene Corporation developed the drug Pomalyst (pomalidomide) for the treatment of multiple myeloma</data>
    </edge>
    <edge id="e144" source="61" target="13">
      <data key="d3">29.0</data>
      <data key="d4">anti-angiogenic drug used...</data>
      <data key="d6">Pomalyst is an anti-angiogenic drug used to treat multiple myeloma, a type of cancer that affects the plasma cells in the bone marrow. Multiple myeloma is a serious and complex disease that can lead to a variety of complications, including bone damage, kidney problems, and an increased risk of infections.

Pomalyst works by restraining the growth of myeloma cells, which are the abnormal plasma cells that accumulate in the bone marrow and disrupt the normal function of the immune system. By inhibiting angiogenesis, or the formation of new blood vessels, Pomalyst helps to starve the myeloma cells of the nutrients and oxygen they need to survive and proliferate.

Pomalyst is typically used in combination with other medications, such as dexamethasone, to treat patients with multiple myeloma who have received at least two prior therapies and have not responded well to other treatments. The drug has been shown to be effective in improving the overall survival and progression-free survival of patients with multiple myeloma, and it can also help to alleviate some of the symptoms associated with the disease, such as bone pain and fatigue.

Despite its effectiveness, Pomalyst can also have some side effects, including fatigue, diarrhea, constipation, and a higher risk of infections. Patients taking Pomalyst may also need to be monitored closely for any changes in their blood counts or other potential complications.

Overall, Pomalyst is an important treatment option for patients with multiple myeloma who have exhausted other treatment options. By targeting the growth and survival of myeloma cells, Pomalyst can help to improve the quality of life and extend the lifespan of patients with this challenging and complex disease.</data>
    </edge>
    <edge id="e145" source="61" target="117">
      <data key="d3">9.0</data>
      <data key="d4">Pomalyst treatment...</data>
      <data key="d6">The FDA approved Pomalyst for the treatment of multiple myeloma in February 2013</data>
    </edge>
    <edge id="e146" source="61" target="118">
      <data key="d3">8.0</data>
      <data key="d4">marketing authorization application...</data>
      <data key="d6">Celgene submitted a marketing authorization application (MAA) for Pomalyst to the EMA in June 2012</data>
    </edge>
    <edge id="e147" source="61" target="119">
      <data key="d3">1.0</data>
      <data key="d4">Pomalyst (under brand...</data>
      <data key="d6">The EC approved Pomalyst (under the brand name IMNOVID) for the treatment of relapsed and refractory multiple myeloma in August 2013</data>
    </edge>
    <edge id="e148" source="13" target="116">
      <data key="d3">1.0</data>
      <data key="d4">Society provides estimates...</data>
      <data key="d6">The American Cancer Society provides estimates on the number of new cases and deaths from multiple myeloma in the US</data>
    </edge>
    <edge id="e149" source="61" target="0">
      <data key="d3">9.0</data>
      <data key="d4">conducted clinical trials...</data>
      <data key="d6">Celgene developed and conducted clinical trials on the drug Pomalyst for the treatment of multiple myeloma</data>
    </edge>
    <edge id="e150" source="61" target="120">
      <data key="d3">8.0</data>
      <data key="d4">clinical trial evaluated...</data>
      <data key="d6">The Phase I clinical trial evaluated the safety, efficacy, tolerability and pharmacokinetics of Pomalyst</data>
    </edge>
    <edge id="e151" source="61" target="121">
      <data key="d3">8.0</data>
      <data key="d4">clinical trial evaluated...</data>
      <data key="d6">The Phase I/II clinical trial evaluated Pomalyst in combination with high dose Dexamethasone and oral cyclophosphamide</data>
    </edge>
    <edge id="e152" source="61" target="122">
      <data key="d3">9.0</data>
      <data key="d4">CC-4047-MM-002 study evaluated...</data>
      <data key="d6">The Phase II CC-4047-MM-002 study evaluated Pomalyst alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma</data>
    </edge>
    <edge id="e153" source="61" target="123">
      <data key="d3">9.0</data>
      <data key="d4">MM-003 study evaluated...</data>
      <data key="d6">The Phase III MM-003 study evaluated time to disease progression or death in patients treated with Pomalyst</data>
    </edge>
    <edge id="e154" source="61" target="124">
      <data key="d3">9.0</data>
      <data key="d4">Pomalyst based results...</data>
      <data key="d6">The FDA approved Pomalyst based on the results from the Phase II CC-4047-MM-002 study</data>
    </edge>
    <edge id="e155" source="61" target="125">
      <data key="d3">9.0</data>
      <data key="d4">Pomalyst based results...</data>
      <data key="d6">The EC approved Pomalyst based on the results from the Phase III MM-003 study</data>
    </edge>
    <edge id="e156" source="61" target="14">
      <data key="d3">8.0</data>
      <data key="d4">combination with Pomalyst...</data>
      <data key="d6">Dexamethasone was used in combination with Pomalyst in clinical trials</data>
    </edge>
    <edge id="e157" source="127" target="1">
      <data key="d3">18.0</data>
      <data key="d4">developed pomalidomide, anti-cancer...</data>
      <data key="d6">Bristol Myers Squibb developed pomalidomide, the anti-cancer medication.</data>
    </edge>
    <edge id="e158" source="128" target="1">
      <data key="d3">16.0</data>
      <data key="d4">medical use...</data>
      <data key="d6">Pomalidomide was approved for medical use in the United States in February 2013.</data>
    </edge>
    <edge id="e159" source="129" target="1">
      <data key="d3">9.0</data>
      <data key="d4">medical use...</data>
      <data key="d6">Pomalidomide was approved for medical use in the European Union in August 2013.</data>
    </edge>
    <edge id="e160" source="1" target="130">
      <data key="d3">1.0</data>
      <data key="d4">treat AIDS-related Kaposi...</data>
      <data key="d6">Pomalidomide is used to treat AIDS-related Kaposi sarcoma.</data>
    </edge>
    <edge id="e161" source="60" target="61">
      <data key="d3">5.0</data>
      <data key="d4">same drug, with...</data>
      <data key="d6">Pomalyst and Imnovid are the same drug, with Imnovid being the brand name used in Europe.</data>
    </edge>
    <edge id="e162" source="60" target="0">
      <data key="d3">17.0</data>
      <data key="d4">pharmaceutical product manufactured...</data>
      <data key="d6">IMNOVID is a pharmaceutical product manufactured and sold by the pharmaceutical company CELGENE. Imnovid was previously known as Pomalidomide Celgene, before being rebranded under the name Imnovid.

CELGENE is the pharmaceutical company responsible for the development, manufacturing, and distribution of the drug IMNOVID. The company has been involved with the product since its initial development and launch, when it was known as Pomalidomide Celgene. At some point, the decision was made to rebrand the product under the new name of IMNOVID, though the underlying drug compound remains the same.

The comprehensive summary of the information provided is that IMNOVID is a pharmaceutical product owned and marketed by the CELGENE corporation. It was initially launched under the name Pomalidomide Celgene, but has since been rebranded and is now sold exclusively under the IMNOVID name. CELGENE maintains full control and responsibility for this drug product.</data>
    </edge>
    <edge id="e163" source="60" target="13">
      <data key="d3">28.0</data>
      <data key="d4">MYELOMA Imnovid medication...</data>
      <data key="d6">IMNOVID and MULTIPLE MYELOMA

Imnovid is a medication used to treat multiple myeloma, a type of blood cancer. Multiple myeloma is a cancer that affects plasma cells, a type of white blood cell responsible for producing antibodies. Imnovid is specifically indicated for the treatment of multiple myeloma in adult patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and whose disease has progressed on the last therapy.

Imnovid is an immunomodulatory drug that works by modulating the immune system and inhibiting the growth of cancer cells. It is typically used in combination with dexamethasone, another medication that helps to enhance the effects of Imnovid. The combination of Imnovid and dexamethasone has been shown to be effective in improving outcomes for patients with multiple myeloma who have received prior treatments.

Multiple myeloma is a serious and complex disease that can be challenging to treat. It is characterized by the uncontrolled growth and accumulation of abnormal plasma cells in the bone marrow, which can lead to a variety of complications, including bone pain, fractures, anemia, and kidney problems. Imnovid, along with other treatments, can help to manage the symptoms of multiple myeloma and improve the quality of life for patients living with this condition.

In summary, Imnovid is a medication used to treat multiple myeloma, a type of blood cancer that affects plasma cells. It is typically used in combination with dexamethasone and is indicated for patients who have received at least two prior therapies. Imnovid works by modulating the immune system and inhibiting the growth of cancer cells, helping to manage the symptoms of multiple myeloma and improve outcomes for patients.</data>
    </edge>
    <edge id="e164" source="60" target="114">
      <data key="d3">8.0</data>
      <data key="d4">OPTIMISMM clinical trial...</data>
      <data key="d6">Imnovid was studied in the OPTIMISMM clinical trial for the treatment of multiple myeloma.</data>
    </edge>
    <edge id="e165" source="0" target="61">
      <data key="d3">8.0</data>
      <data key="d4">sold pharmaceutical...</data>
      <data key="d6">Pomalyst is manufactured and sold by the pharmaceutical company Celgene.</data>
    </edge>
    <edge id="e166" source="13" target="61">
      <data key="d3">9.0</data>
      <data key="d4">treat blood cancer...</data>
      <data key="d6">Pomalyst is used to treat the blood cancer multiple myeloma.</data>
    </edge>
    <edge id="e167" source="13" target="115">
      <data key="d3">9.0</data>
      <data key="d4">treat blood cancer...</data>
      <data key="d6">Revlimid is used to treat the blood cancer multiple myeloma.</data>
    </edge>
    <edge id="e168" source="61" target="114">
      <data key="d3">8.0</data>
      <data key="d4">OPTIMISMM clinical trial...</data>
      <data key="d6">Pomalyst was studied in the OPTIMISMM clinical trial for the treatment of multiple myeloma.</data>
    </edge>
    <edge id="e169" source="131" target="1">
      <data key="d3">8.0</data>
      <data key="d4">developing drug pomalidomide,...</data>
      <data key="d6">Bristol-Myers Squibb is developing the drug pomalidomide, which is the active ingredient in Pomalyst and Imnovid.</data>
    </edge>
    <edge id="e170" source="1" target="132">
      <data key="d3">1.0</data>
      <data key="d4">ingredient Pomalyst Imnovid,...</data>
      <data key="d6">Pomalidomide, the active ingredient in Pomalyst and Imnovid, is being developed by Bristol-Myers Squibb for the treatment of acute myelocytic leukemia.</data>
    </edge>
    <edge id="e171" source="1" target="131">
      <data key="d3">18.0</data>
      <data key="d4">pharmaceutical company developing...</data>
      <data key="d6">Bristol-Myers Squibb is the pharmaceutical company developing the drug pomalidomide for the treatment of acute myelocytic leukemia (AML)</data>
    </edge>
    <edge id="e172" source="1" target="133">
      <data key="d3">2.0</data>
      <data key="d4">developed Bristol-Myers Squibb...</data>
      <data key="d6">Pomalidomide is being developed by Bristol-Myers Squibb as a treatment for acute myelocytic leukemia (AML)</data>
    </edge>
    <edge id="e173" source="61" target="55">
      <data key="d3">8.0</data>
      <data key="d4">women discontinue breastfeeding...</data>
      <data key="d6">POMALYST advises nursing women to discontinue breastfeeding during treatment due to the potential for adverse reactions in breastfed infants</data>
    </edge>
    <edge id="e174" source="61" target="134">
      <data key="d3">7.0</data>
      <data key="d4">POMALYST have not...</data>
      <data key="d6">Safety and effectiveness of POMALYST have not been established in pediatric patients</data>
    </edge>
    <edge id="e175" source="61" target="135">
      <data key="d3">7.0</data>
      <data key="d4">years old were...</data>
      <data key="d6">Patients over 65 years old were more likely to experience pneumonia when taking POMALYST</data>
    </edge>
    <edge id="e176" source="61" target="38">
      <data key="d3">8.0</data>
      <data key="d4">should reduced...</data>
      <data key="d6">Dose of POMALYST should be reduced by 25% in patients with severe renal impairment requiring dialysis</data>
    </edge>
    <edge id="e177" source="61" target="136">
      <data key="d3">8.0</data>
      <data key="d4">should reduced...</data>
      <data key="d6">Dose of POMALYST should be reduced by 25% in patients with mild to moderate hepatic impairment and 50% in patients with severe hepatic impairment</data>
    </edge>
    <edge id="e178" source="61" target="137">
      <data key="d3">1.0</data>
      <data key="d4">efficacy POMALYST...</data>
      <data key="d6">Smoking may reduce the efficacy of POMALYST as it reduces the AUC of pomalidomide by 32% through CYP1A2 induction</data>
    </edge>
    <edge id="e179" source="61" target="144">
      <data key="d3">8.0</data>
      <data key="d4">used study effects...</data>
      <data key="d6">Lactating rats were used to study the effects of POMALYST on milk production</data>
    </edge>
    <edge id="e180" source="61" target="138">
      <data key="d3">8.0</data>
      <data key="d4">experience adverse reactions...</data>
      <data key="d6">Breastfed infants may experience adverse reactions from POMALYST excreted in breast milk</data>
    </edge>
    <edge id="e181" source="61" target="139">
      <data key="d3">8.0</data>
      <data key="d4">POMALYST have not...</data>
      <data key="d6">Safety and effectiveness of POMALYST have not been established in pediatric patients</data>
    </edge>
    <edge id="e182" source="61" target="140">
      <data key="d3">8.0</data>
      <data key="d4">years old were...</data>
      <data key="d6">Patients over 65 years old were more likely to experience pneumonia when taking POMALYST</data>
    </edge>
    <edge id="e183" source="61" target="141">
      <data key="d3">8.0</data>
      <data key="d4">should reduced...</data>
      <data key="d6">Dose of POMALYST should be reduced by 25% in patients with severe renal impairment requiring dialysis</data>
    </edge>
    <edge id="e184" source="61" target="142">
      <data key="d3">8.0</data>
      <data key="d4">should reduced...</data>
      <data key="d6">Dose of POMALYST should be reduced by 25% in patients with mild to moderate hepatic impairment and 50% in patients with severe hepatic impairment</data>
    </edge>
    <edge id="e185" source="61" target="143">
      <data key="d3">1.0</data>
      <data key="d4">efficacy POMALYST...</data>
      <data key="d6">Smoking may reduce the efficacy of POMALYST as it reduces the AUC of pomalidomide by 32% through CYP1A2 induction</data>
    </edge>
    <edge id="e186" source="118" target="60">
      <data key="d3">18.0</data>
      <data key="d4">responsible authorizing use...</data>
      <data key="d6">The EMA is responsible for authorizing the use of Imnovid in the European Union.</data>
    </edge>
    <edge id="e187" source="60" target="1">
      <data key="d3">27.0</data>
      <data key="d4">related entities. Pomalidomide...</data>
      <data key="d6">IMNOVID and POMALIDOMIDE are related entities. Pomalidomide is the active substance in the cancer medicine Imnovid.

Imnovid is a medication used to treat multiple myeloma, a type of blood cancer. Pomalidomide, the active substance in Imnovid, is a type of immunomodulatory drug that works by modulating the immune system to help fight cancer cells.

Pomalidomide is the key ingredient in Imnovid, and the two terms can be used interchangeably to refer to the same medication. Imnovid, which contains pomalidomide as the active substance, is approved for the treatment of multiple myeloma in adults who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and whose disease has progressed on the last therapy.

Pomalidomide, the active substance in Imnovid, is believed to work by inhibiting the growth and survival of multiple myeloma cells, as well as by stimulating the immune system to attack the cancer cells. It may also have anti-angiogenic properties, meaning it can help prevent the formation of new blood vessels that feed the tumor.

Imnovid, containing pomalidomide, is typically taken orally in combination with other medications, such as dexamethasone, to treat multiple myeloma. The specific dosage and treatment regimen will be determined by the healthcare provider based on the individual patient's needs and response to the therapy.

In summary, Imnovid and pomalidomide are closely related, as pomalidomide is the active substance in the cancer medication Imnovid. Imnovid, containing pomalidomide, is used to treat multiple myeloma in adults who have received prior therapies and whose disease has progressed.</data>
    </edge>
    <edge id="e188" source="60" target="16">
      <data key="d3">17.0</data>
      <data key="d4">used combination...</data>
      <data key="d6">IMNOVID and BORTEZOMIB are used in combination to treat multiple myeloma, a type of cancer that affects the plasma cells in the bone marrow.

IMNOVID is a medication that is used in combination with BORTEZOMIB, another cancer treatment, to treat multiple myeloma. Multiple myeloma is a type of cancer that affects the plasma cells, which are a type of white blood cell that produces antibodies. IMNOVID works by interfering with the growth and division of cancer cells, helping to slow the progression of the disease.

BORTEZOMIB is a cancer medication that is also used in combination with IMNOVID to treat multiple myeloma. BORTEZOMIB works by inhibiting the activity of a protein complex called the proteasome, which is responsible for breaking down and recycling proteins within the cell. By inhibiting the proteasome, BORTEZOMIB can cause the accumulation of proteins within the cancer cells, leading to their death.

The combination of IMNOVID and BORTEZOMIB has been shown to be an effective treatment for multiple myeloma. When used together, the two medications work to target the cancer cells from different angles, making it more difficult for the cancer to develop resistance to the treatment. This combination therapy has been shown to improve the overall survival and quality of life for patients with multiple myeloma.

Overall, IMNOVID and BORTEZOMIB are important medications in the treatment of multiple myeloma. When used in combination, they can help to slow the progression of the disease and improve the outcomes for patients with this type of cancer.</data>
    </edge>
    <edge id="e189" source="60" target="14">
      <data key="d3">17.0</data>
      <data key="d4">used combination...</data>
      <data key="d6">IMNOVID and DEXAMETHASONE are used in combination to treat multiple myeloma, a type of cancer that affects the plasma cells in the bone marrow.

Imnovid (also known as pomalidomide) is an immunomodulatory drug that works by modulating the immune system to help fight the cancer cells. It is used in combination with the anti-inflammatory medicine dexamethasone to treat multiple myeloma in patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.

Dexamethasone is a corticosteroid that helps reduce inflammation and swelling in the body. When used in combination with Imnovid, dexamethasone enhances the anti-cancer effects of Imnovid and helps manage any side effects that may occur.

The combination of Imnovid and dexamethasone has been shown to be effective in treating multiple myeloma, particularly in patients whose disease has relapsed or become resistant to other treatments. Clinical studies have demonstrated that this combination can help improve progression-free survival and overall survival in these patients.

Imnovid is typically taken orally, while dexamethasone can be taken orally or intravenously. The dosage and schedule of the two medications are carefully monitored and adjusted by healthcare providers to ensure the best possible outcomes for the patient.

It is important for patients taking Imnovid and dexamethasone to be closely monitored for potential side effects, which may include fatigue, diarrhea, constipation, and low blood cell counts. Patients should also be aware of the increased risk of blood clots and should take appropriate precautions, such as wearing compression stockings or taking blood-thinning medications, if necessary.

Overall, the combination of Imnovid and dexamethasone represents an important treatment option for patients with multiple myeloma who have received prior therapies. By working together to modulate the immune system and reduce inflammation, these two medications can help improve the outcomes for patients with this challenging and complex disease.</data>
    </edge>
    <edge id="e190" source="60" target="15">
      <data key="d3">2.0</data>
      <data key="d4">two related pharmaceutical...</data>
      <data key="d6">IMNOVID and LENALIDOMIDE are two related pharmaceutical products used in the treatment of certain medical conditions.

LENALIDOMIDE is a medication that has been used as a treatment option for patients. The descriptions provided indicate that patients must have received at least one prior treatment that included lenalidomide before they can be eligible for treatment with IMNOVID.

IMNOVID is another medication that is used in the treatment of patients. The descriptions state that patients receiving IMNOVID must have received prior treatment with lenalidomide. This suggests that IMNOVID is typically used as a subsequent or follow-up treatment option for patients who have already been treated with lenalidomide.

The descriptions do not provide any contradictory information about the use of these two medications. Instead, they consistently indicate that IMNOVID is intended for use in patients who have already been treated with lenalidomide. This suggests that IMNOVID is likely a more specialized or advanced treatment option that is reserved for patients who have not responded adequately to lenalidomide or have experienced a recurrence of their condition after initial treatment with lenalidomide.

In summary, LENALIDOMIDE is a medication that is used as an initial or primary treatment option, while IMNOVID is a subsequent or follow-up treatment that is reserved for patients who have already been treated with lenalidomide. The use of these two medications appears to be part of a comprehensive treatment approach for managing certain medical conditions.</data>
    </edge>
    <edge id="e191" source="12" target="60">
      <data key="d3">10.0</data>
      <data key="d4">Agency (EMA) regulatory...</data>
      <data key="d6">The European Medicines Agency (EMA) is the regulatory body responsible for evaluating and authorizing the use of pharmaceutical products within the European Union (EU). One such product that the EMA has evaluated and authorized is Imnovid, a medication used for the treatment of multiple myeloma.

According to the information provided, the EMA has determined that the benefits of Imnovid outweigh its risks for treating multiple myeloma patients who have limited treatment options. The EMA's authorization of Imnovid means that the agency has concluded that the drug is safe and effective for its intended use, and that it can be made available to patients in the EU.

Imnovid, also known by its generic name pomalidomide, is a type of medication called an immunomodulatory drug. It works by modulating the immune system and inhibiting the growth and survival of myeloma cells. Imnovid is typically used in combination with other drugs, such as dexamethasone, to treat patients with multiple myeloma who have received at least two prior therapies and whose disease has progressed.

The EMA's decision to authorize Imnovid was based on the results of clinical trials that demonstrated the drug's efficacy and safety in treating multiple myeloma. These trials showed that Imnovid, when used in combination with dexamethasone, can significantly improve progression-free survival and overall survival in patients with relapsed or refractory multiple myeloma.

The EMA's evaluation of Imnovid likely included a thorough review of the drug's clinical data, as well as an assessment of its potential risks and benefits. The agency's decision to authorize the use of Imnovid in the EU suggests that the drug's benefits for multiple myeloma patients outweigh its potential risks, and that it represents a valuable treatment option for those with limited treatment alternatives.

In summary, the European Medicines Agency has authorized the use of Imnovid (pomalidomide) in the EU for the treatment of multiple myeloma patients with limited treatment options, based on its determination that the drug's benefits outweigh its risks. This decision provides patients in the EU with access to an additional treatment option for this serious and often difficult-to-treat form of cancer.</data>
    </edge>
    <edge id="e192" source="0" target="60">
      <data key="d3">9.0</data>
      <data key="d4">company that manufactures...</data>
      <data key="d6">Celgene is the company that manufactures Imnovid</data>
    </edge>
    <edge id="e193" source="0" target="145">
      <data key="d3">9.0</data>
      <data key="d4">Imnovid, will set...</data>
      <data key="d6">Celgene, the manufacturer of Imnovid, will set up a pregnancy-prevention program in each EU member state</data>
    </edge>
    <edge id="e194" source="16" target="60">
      <data key="d3">8.0</data>
      <data key="d4">combination with bortezomib...</data>
      <data key="d6">Imnovid is used in combination with bortezomib and dexamethasone to treat multiple myeloma patients who have received at least one prior treatment including lenalidomide</data>
    </edge>
    <edge id="e195" source="14" target="60">
      <data key="d3">8.0</data>
      <data key="d4">combination with bortezomib...</data>
      <data key="d6">Imnovid is used in combination with bortezomib and dexamethasone to treat multiple myeloma patients who have received at least one prior treatment including lenalidomide</data>
    </edge>
    <edge id="e196" source="15" target="60">
      <data key="d3">1.0</data>
      <data key="d4">treat multiple myeloma...</data>
      <data key="d6">Imnovid is used to treat multiple myeloma patients who have received at least one prior treatment including lenalidomide</data>
    </edge>
    <edge id="e197" source="145" target="146">
      <data key="d3">1.0</data>
      <data key="d4">states will ensure...</data>
      <data key="d6">The EU member states will ensure the educational materials and patient cards are provided for the pregnancy-prevention program</data>
    </edge>
    <edge id="e198" source="60" target="12">
      <data key="d3">11.0</data>
      <data key="d4">Agency (EMA) regulatory...</data>
      <data key="d6">The European Medicines Agency (EMA) is the regulatory body responsible for the scientific evaluation and approval of the medicinal product IMNOVID. In 2009, the EMA designated IMNOVID as an orphan medicine, recognizing its potential to treat a rare and serious condition. This designation provided IMNOVID with certain benefits, such as market exclusivity and financial incentives, to support its development and eventual approval.

However, in 2023, the EMA made the decision to withdraw IMNOVID from the orphan register. This withdrawal suggests that the EMA no longer considers IMNOVID to meet the criteria for an orphan medicine, either due to changes in the understanding of the target condition or the availability of alternative treatment options.

Despite the withdrawal from the orphan register, the EMA remains responsible for the overall evaluation and approval of IMNOVID as a medicinal product. The agency's scientific assessment and approval process ensures that IMNOVID meets the necessary standards of safety, efficacy, and quality before it can be made available to patients.

The EMA's role in the regulation of IMNOVID highlights its importance as the central regulatory authority for medicines in Europe. The agency's decisions, such as the initial orphan designation and the subsequent withdrawal, are based on a comprehensive review of the available scientific evidence and are aimed at ensuring the appropriate use and availability of medicines for European patients.

In summary, the European Medicines Agency (EMA) is the regulatory body responsible for the scientific evaluation and approval of the medicinal product IMNOVID. The EMA initially designated IMNOVID as an orphan medicine in 2009, but later withdrew this designation in 2023. The EMA's oversight and decision-making process regarding IMNOVID are crucial in ensuring the safe and effective use of this medication for European patients.</data>
    </edge>
    <edge id="e199" source="60" target="147">
      <data key="d3">8.0</data>
      <data key="d4">Plan document specific...</data>
      <data key="d6">The Risk Management Plan is a document specific to the medicinal product Imnovid</data>
    </edge>
    <edge id="e200" source="60" target="148">
      <data key="d3">1.0</data>
      <data key="d4">document provides details...</data>
      <data key="d6">The Product Information document provides details about the medicinal product Imnovid</data>
    </edge>
    <edge id="e201" source="60" target="149">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in English</data>
    </edge>
    <edge id="e202" source="60" target="150">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Bulgarian</data>
    </edge>
    <edge id="e203" source="60" target="151">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Spanish</data>
    </edge>
    <edge id="e204" source="60" target="152">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Czech</data>
    </edge>
    <edge id="e205" source="60" target="153">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Danish</data>
    </edge>
    <edge id="e206" source="60" target="154">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in German</data>
    </edge>
    <edge id="e207" source="60" target="155">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Estonian</data>
    </edge>
    <edge id="e208" source="60" target="156">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Greek</data>
    </edge>
    <edge id="e209" source="60" target="157">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in French</data>
    </edge>
    <edge id="e210" source="60" target="158">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Croatian</data>
    </edge>
    <edge id="e211" source="60" target="159">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Icelandic</data>
    </edge>
    <edge id="e212" source="60" target="160">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Italian</data>
    </edge>
    <edge id="e213" source="60" target="161">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Latvian</data>
    </edge>
    <edge id="e214" source="60" target="162">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Lithuanian</data>
    </edge>
    <edge id="e215" source="60" target="163">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Hungarian</data>
    </edge>
    <edge id="e216" source="60" target="164">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Maltese</data>
    </edge>
    <edge id="e217" source="60" target="165">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Dutch</data>
    </edge>
    <edge id="e218" source="60" target="166">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Norwegian</data>
    </edge>
    <edge id="e219" source="60" target="167">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Polish</data>
    </edge>
    <edge id="e220" source="60" target="168">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Portuguese</data>
    </edge>
    <edge id="e221" source="60" target="169">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Romanian</data>
    </edge>
    <edge id="e222" source="60" target="170">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Slovak</data>
    </edge>
    <edge id="e223" source="60" target="171">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Slovenian</data>
    </edge>
    <edge id="e224" source="60" target="172">
      <data key="d3">8.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Finnish</data>
    </edge>
    <edge id="e225" source="60" target="173">
      <data key="d3">1.0</data>
      <data key="d4">risk management plan...</data>
      <data key="d6">The product information and risk management plan for Imnovid is published in Swedish</data>
    </edge>
    <edge id="e226" source="147" target="12">
      <data key="d3">8.0</data>
      <data key="d4">Agency requires Risk...</data>
      <data key="d6">The European Medicines Agency requires a Risk Management Plan to be submitted for the medicinal product Imnovid</data>
    </edge>
    <edge id="e227" source="148" target="12">
      <data key="d3">8.0</data>
      <data key="d4">Agency publishes Product...</data>
      <data key="d6">The European Medicines Agency publishes the Product Information document for the medicinal product Imnovid</data>
    </edge>
    <edge id="e228" source="12" target="129">
      <data key="d3">9.0</data>
      <data key="d4">Agency operates within...</data>
      <data key="d6">The European Medicines Agency operates within the European Union</data>
    </edge>
    <edge id="e229" source="60" target="174">
      <data key="d3">1.0</data>
      <data key="d4">latest procedure affecting...</data>
      <data key="d6">PASS is responsible for the latest procedure affecting the product information for Imnovid</data>
    </edge>
    <edge id="e230" source="60" target="129">
      <data key="d3">9.0</data>
      <data key="d4">available all official...</data>
      <data key="d6">Imnovid's product information is available in all official EU languages</data>
    </edge>
    <edge id="e231" source="60" target="175">
      <data key="d3">9.0</data>
      <data key="d4">summary product characteristics...</data>
      <data key="d6">Annex I contains the summary of product characteristics for Imnovid</data>
    </edge>
    <edge id="e232" source="60" target="176">
      <data key="d3">9.0</data>
      <data key="d4">manufacturing authorisation holder...</data>
      <data key="d6">Annex IIA contains the manufacturing authorisation holder responsible for batch release of Imnovid</data>
    </edge>
    <edge id="e233" source="60" target="177">
      <data key="d3">9.0</data>
      <data key="d4">conditions marketing...</data>
      <data key="d6">Annex IIB contains the conditions of the marketing authorisation for Imnovid</data>
    </edge>
    <edge id="e234" source="60" target="178">
      <data key="d3">9.0</data>
      <data key="d4">labelling Imnovid...</data>
      <data key="d6">Annex IIIA contains the labelling for Imnovid</data>
    </edge>
    <edge id="e235" source="60" target="179">
      <data key="d3">1.0</data>
      <data key="d4">package leaflet Imnovid...</data>
      <data key="d6">Annex IIIB contains the package leaflet for Imnovid</data>
    </edge>
    <edge id="e236" source="60" target="180">
      <data key="d3">9.0</data>
      <data key="d4">EEIG marketing authorization...</data>
      <data key="d6">Bristol-Myers Squibb Pharma EEIG is the marketing authorization holder for Imnovid</data>
    </edge>
    <edge id="e237" source="180" target="181">
      <data key="d3">5.0</data>
      <data key="d4">EEIG located Plaza...</data>
      <data key="d6">Bristol-Myers Squibb Pharma EEIG is located at Plaza 254</data>
    </edge>
    <edge id="e238" source="180" target="182">
      <data key="d3">5.0</data>
      <data key="d4">EEIG located Blanchardstown...</data>
      <data key="d6">Bristol-Myers Squibb Pharma EEIG is located at Blanchardstown Corporate Park 2</data>
    </edge>
    <edge id="e239" source="180" target="183">
      <data key="d3">5.0</data>
      <data key="d4">EEIG located Dublin...</data>
      <data key="d6">Bristol-Myers Squibb Pharma EEIG is located in Dublin 15 D15 T867</data>
    </edge>
    <edge id="e240" source="180" target="126">
      <data key="d3">1.0</data>
      <data key="d4">EEIG located Ireland...</data>
      <data key="d6">Bristol-Myers Squibb Pharma EEIG is located in Ireland</data>
    </edge>
    <edge id="e241" source="129" target="60">
      <data key="d3">18.0</data>
      <data key="d4">authorized marketing...</data>
      <data key="d6">Imnovid has been authorized for marketing in the European Union</data>
    </edge>
    <edge id="e242" source="184" target="60">
      <data key="d3">10.0</data>
      <data key="d4">reviewed provided opinions...</data>
      <data key="d6">The CHMP has reviewed and provided opinions on the marketing authorization for Imnovid</data>
    </edge>
    <edge id="e243" source="184" target="12">
      <data key="d3">1.0</data>
      <data key="d4">committee within European...</data>
      <data key="d6">The CHMP is a committee within the European Medicines Agency</data>
    </edge>
    <edge id="e244" source="60" target="185">
      <data key="d3">9.0</data>
      <data key="d4">Community register...</data>
      <data key="d6">Imnovid was listed in the Community register of orphan medicinal products from 2009 until its withdrawal in 2023</data>
    </edge>
  </graph>
</graphml>